| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
HUTCHMED (China) Limited$11.07
+0.09 (+0.82%)
B 73Pipeline Score Undervalued Pharma · Commercial
Market Cap
2.13 B
EPS
2.67
P/E Ratio
4.57 $
Value Trade
1.11 M
-4.23 %
Week
-20.01 %
1 Month
-19.69 %
3 Month
-14.66 %
6 Month
-57.18 %
5 Year
-11.19 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
37.48 K
52 Week Range
11.72 - 19.50
% held by Insiders
2.3 %
% held by Institutions
2.53 %
Enterprise Value
877.59 M
Total Shares
174.47 M
Short %
0.12 %
Float Shares
170.46 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for HUTCHMED (China) Limited
1076Total events
3Upcoming
302Tier-1 (high impact)
2015 – 2026Coverage
Upcoming catalysts 3
Event history 1073
Jun 11, 2026
Jun 11, 2026
◆Oral PresentationsovleplenibPresentation
ESLIM-02 Phase III data presented at EHA 2026 Congress
warm antibody autoimmune hemolytic anemiasource ↗
Jun 11, 2026
▲Primary Endpoint MetsovleplenibClinical Data
ESLIM-02 met primary endpoint: durable response rate 66% vs 15%
warm antibody autoimmune hemolytic anemiasource ↗
Jun 5, 2026
●Equity OfferingCorporate
Block admission application for 43,616,756 ordinary shares under 2026 Share Option Scheme
Jun 1, 2026
◆Oral PresentationSavolitinibApprovedPresentation
Phase 2 pivotal study of savolitinib in MET-amplified gastric cancer/GEJ adenocarcinoma rapid oral presentation at ASCO 2026
gastric cancer or gastroesophageal junction adenocarcinomasource ↗
May 29, 2026
◆Poster PresentationfruquintinibApprovedPresentation
Tumor shrinkage and depth of response with fruquintinib in mCRC: Results from FRESCO and FRESCO-2 poster
metastatic colorectal cancersource ↗
May 29, 2026
◆Poster PresentationSurufatinib with Nab-paclitaxel, and GemcitabineApprovedPresentation
Surufatinib + KN046 + chemo as first-line for advanced PDAC: updated results and biomarker analysis poster
pancreatic ductal adenocarcinomasource ↗
May 29, 2026
◆Poster PresentationSavolitinibApprovedPresentation
Osimertinib + savolitinib in osimertinib-resistant NSCLC with low MET GCN: phase 2 study (publication only)
non-small-cell lung cancersource ↗
May 21, 2026
▲NMPA NDA ApprovalELUNATEApprovedEx-US Regulatory
NMPA approval for ELUNATE (fruquintinib) in combination with TYVYT (sintilimab) for RCC
locally advanced or metastatic renal cell carcinomasource ↗
Apr 29, 2026
▲FDA Filing AcceptedsovleplenibRegulatory Filing
NDA accepted for review by NMPA for wAIHA
warm antibody autoimmune hemolytic anemiasource ↗
Apr 29, 2026
▲Priority ReviewsovleplenibRegulatory Filing
Priority review granted by NMPA for wAIHA NDA
warm antibody autoimmune hemolytic anemiasource ↗
Drug Pipeline Intelligence
B73
Pipeline Score $16.1B
Pipeline ValueUndervalued
Valuation Signal27
Drugs Scored7.5x
rNPV / MCap Top 95%
Small Cap (rank 47 of 911)
Percentile RankHUTCHMED (China) Limited holds a solid B-grade pipeline (73/100), with $29.4B risk-adjusted pipeline value, led by Fruquintinib in Tumor (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fruquintinib Small molecule | NSCLC | Phase 3 | NCT02976116 | 90% | $7.9B | COMPLETED | 577 | - | - | Jun 28, 2019 | - | Nov 15, 2019 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
sovleplenib BreakthroughPriority | warm antibody autoimmune hemolytic anemia | Phase 3 | 2026-06-12 | 66% vs 15%, p<0.0001; 70% vs 22%, p<0.0001; 16% vs 54%, p=0.0001; 11% vs 43%; 50% vs 15%, p=0.003; 3.1 weeks vs 6.3 weeks; 16.1 weeks vs 6.1 weeks Read More | HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress - Sovleplenib demonstrated rapid and durable hemoglobin response with favo Read More | |
sovleplenib BreakthroughPriority | warm antibody autoimmune hemolytic anemia | Phase 3 | 2026-06-12 | 66% vs 15%, p<0.0001; 70% vs 22%, p<0.0001; 16% vs 54%, p=0.0001; 11% vs 43%; 50% vs 15%, p=0.003; 3.1 weeks vs 6.3 weeks; 16.1 weeks vs 6.1 weeks Read More | HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress - Sovleplenib demonstrated rapid and durable hemoglobin response with favo Read More | |
sovleplenib BreakthroughPriority | warm antibody autoimmune hemolytic anemia | Phase 3 | 2026-06-12 | 66% vs 15%, p<0.0001; 70% vs 22%, p<0.0001; 16% vs 54%, p=0.0001; 11% vs 43%; 50% vs 15%, p=0.003; 3.1 weeks vs 6.3 weeks; 16.1 weeks vs 6.1 weeks Read More | HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress - Sovleplenib demonstrated rapid and durable hemoglobin response with favo Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in HCM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
HCM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
HCMHUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress - Sovleplenib demonstrated rapid and durable hemoglobin response with favo
HUTCHMED has presented the Phase III ESLIM-02 study results for its investigational drug, sovleplenib, targeting warm antibody autoimmune hemolytic anemia (wAIHA) during the EHA 2026 Congress. The study showed that sovleplenib produced a significantly higher durable response rate and reduced the need for rescue therapies compared to placebo, highlighting its potential to meet urgent treatment needs. In addition, the drug exhibited a favorable safety profile. The positive findings support its New Drug Application, which has been granted priority review in China.
Read more →HCMBlock Admission Application Hong Kong, Shanghai & Florham Park, NJ - Friday, June 5 , 2026: HUTCHMED (China) Limited (" HUTCHMED " or the "Company") (Nasdaq/AIM: HCM; SEHK:13) today announces an application has been made
HUTCHMED (China) Limited has submitted an application for a block admission of 43,616,756 ordinary shares to the London Stock Exchange. This move is part of the company's 2026 Share Option Scheme, which was approved during the annual general meeting on May 12, 2026. The block admission aims to streamline the issuance of shares as options are exercised, with full transparency on the utilization of these shares. The total issued share capital will remain unchanged at 872,335,120 ordinary shares following this application.
Read more →HCMHUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting Hong Kong, Shanghai & Florham Park, NJ - Fri day
HUTCHMED (HCM) announced the presentation of new clinical data at the 2026 ASCO Annual Meeting, scheduled for May 29 to June 2, 2026, in Chicago. Notably, a pivotal Phase II study of savolitinib in patients with MET-amplified gastric cancer demonstrated a significant objective response rate (ORR) of 32.3%. Additionally, various studies on fruquintinib and other compounds will also be presented, indicating a broad scope of ongoing research and development by the company.
Read more →HCMHUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE (Fruquintinib) in Combination with TYVYT (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell
HUTCHMED and Innovent have received NMPA approval for their drug combination ELUNATE and TYVYT to treat patients with locally advanced or metastatic renal cell carcinoma. This approval follows positive results from the FRUSICA-2 trial, which showed that the combination significantly reduces the risk of disease progression, achieving a median progression-free survival of 22.2 months. The treatment aims to address the unmet medical needs of patients who have failed prior therapies. This marks a notable advancement in therapy for patients with challenging cancer types in China.
Read more →HCMAnnual General Meeting held on May 1 2 , 202 6 - Poll Results Hong Kong, Shanghai, & Florham Park, NJ: Tuesday , May 12 , 202 6 : HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM; HKEX:13) today an
HUTCHMED (China) Limited announced the successful results of its Annual General Meeting held on May 12, 2026, where all ordinary and special resolutions were passed. The resolutions included the approval of audited financial statements and the re-election of several directors, with overwhelming support from shareholders. Notably, the company also adopted a new Share Option Scheme for 2026. This meeting reflects strong shareholder confidence in the company's governance and strategic direction.
Read more →HCMTotal Voting Rights Hong Kong, Shanghai & Florham Park, NJ - Thursday
HUTCHMED (China) Limited has reported an update on its issued share capital as of April 30, 2026. The total number of ordinary shares stands at 872,335,120, each carrying one voting right. This figure serves as a benchmark for shareholders to assess their notification obligations under the Financial Conduct Authority's regulations. Additionally, it specifies the equivalence of ordinary shares in terms of depositary interests and American depositary shares traded on different exchanges.
Read more →HCMHUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia Hong Kong, Shanghai & Florh
HUTCHMED has received acceptance for its New Drug Application (NDA) for sovleplenib by the China National Medical Products Administration (NMPA), granted priority review and breakthrough designation. This treatment aims to address warm antibody autoimmune hemolytic anemia (wAIHA), an autoimmune disorder with limited existing therapies. The NDA is bolstered by promising clinical data demonstrating significant hemoglobin response rates. Furthermore, the Phase III trial results are set to be presented at the upcoming European Hematology Association Congress 2026.
Read more →HCMHUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026 Hong Kong, Shanghai & Florham Park, NJ - Thurs day
HUTCHMED (HCM) has announced that it will present new and updated data at the AACR Annual Meeting 2026, showcasing several studies including the first-in-class HMPL-A580, an antibody-targeted therapy conjugate. This compound demonstrated robust anti-tumor effects and selectivity against cancer cell lines expressing EGFR. Additionally, updated results from a multicenter trial of surufatinib combined with other therapeutics will be highlighted. These presentations underscore HUTCHMED's commitment to advancing precision oncology through innovative therapies.
Read more →HCM2025 Annual Report and Notice of Annual General
HUTCHMED (China) Limited announced that its 2025 Annual Report and related AGM materials will be posted on April 10, 2026, for shareholders opting for printed versions. The upcoming 2026 Annual General Meeting is scheduled for May 12, 2026, at the Harbour Grand Kowloon in Hong Kong, available through an electronic platform for those unable to attend in person. HUTCHMED focuses on developing targeted therapies and immunotherapies for cancer and immunological diseases, with its products already marketed in various regions.
Read more →HCMHUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China Hong Kong, Shanghai & Florham Park, NJ - Monday
HUTCHMED has initiated a Phase III trial of its investigational drug HMPL-760 in combination with R-GemOx for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in China. The trial, which started on March 20, 2026, aims to evaluate efficacy and safety in approximately 240 patients. HMPL-760 has shown promise in prior studies and targets Bruton's tyrosine kinase (BTK), a key factor in DLBCL treatment resistance. Although progress has been made, future outcomes are subject to various clinical and regulatory challenges.
Read more →HCMVesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ - Monday, March 16 , 202 5 : HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance
HUTCHMED (China) Limited announced the vesting of non-performance based awards under its Long Term Incentive Plan for Dr. Weiguo Su, the Executive Director, CEO, and Chief Scientific Officer. The awards, granted on March 13, 2024, were vested on March 13, 2026. This notification fulfills the requirements of the UK Market Abuse Regulation.
Read more →HCMVesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ - Wednesday
HUTCHMED (China) Limited has announced the successful vesting of awards under its Long Term Incentive Plan for two executive directors, Dr. Weiguo Su and Mr. Johnny Cheng, on March 10, 2026. The awards, which included a total of 726,317 ordinary shares, were granted on June 5, 2023. This vesting followed the company's announcement of its 2025 annual results on March 5, 2026, and serves to align the interests of the executive team with those of the shareholders.
Read more →HCMHUTCHMED Announces Update on Licensed Oncology Product TAZVERIK in China Hong Kong, Shanghai & Florham Park, NJ - Monday
HUTCHMED has announced a market withdrawal and product recall of TAZVERIK in China due to Ipsen's decision to withdraw the oncology drug in the US over safety concerns regarding secondary hematologic malignancies. As a result, HUTCHMED will discontinue all active clinical trials involving tazemetostat and has informed healthcare authorities and professionals about the situation. Patients currently receiving tazemetostat are urged to consult with their physicians regarding alternative treatment options, while the company continues to cooperate with regulatory authorities on the next steps for the withdrawal.
Read more →HCMIntended r etirement of Independent Non-executive Director and changes of composition of board committees Hong Kong, Shanghai & Florham Park, NJ - Friday
HUTCHMED (China) Limited announced the upcoming retirement of Professor Mok Shu Kam, Tony, an Independent Non-executive Director, who will not seek re-election at the annual general meeting on May 12, 2026. Professor Mok's tenure will conclude, marking nearly nine years of service, during which he played a significant role in strengthening the Board and guiding the Company's scientific efforts. Alongside his retirement, there will be changes to the composition of board committees pending re-elections at the AGM. The Board expressed gratitude for Professor Mok's contributions, emphasizing the impact of his leadership on HUTCHMED’s strategy.
Read more →HCMHUTCHMED Reports 2025 Full Year Results and Business Updates - Geographic expansion driving ex-China sales growth; indication expansions driving China sales growth - - $457 million net income, driven by profitable core o
HUTCHMED reported its 2025 full-year results showcasing a net income of $457 million, attributed to its profitable core operations and geographic expansion beyond China. The company has seen substantial growth in sales of its key product, FRUZAQLA, while also mentioning challenges such as a 21% decline in oncology product revenues due to market headwinds. HUTCHMED expressed optimism for future growth supported by a robust pipeline and a strong financial position with $1.4 billion in cash, positioning them well for continued investment in innovative drug development.
Read more →HCMHUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors - Second clinical candidate from HUTCHMED's next-generation ATTC platform - - Leveraging synergy thro
HUTCHMED has initiated a global Phase I/IIa clinical trial for HMPL-A580, its second Antibody-Targeted Therapy Conjugate (ATTC), targeting advanced solid tumors. This candidate aims to synergize PAM pathway inhibition with anti-EGFR therapy, employing a unique link between a selective PI3K/PIKK inhibitor and an anti-EGFR antibody. The trial, which has begun dosing patients in China and the US, will assess safety, pharmacokinetics, and preliminary efficacy. HUTCHMED's ATTC platform is positioned as a novel approach to enhance targeted therapy responses.
Read more →HCMHUTCHMED to Announce 2025 Final Results Hong Kong, Shanghai & Florham Park, NJ - Friday
HUTCHMED (China) Limited has announced that it will present its final results for the year ended December 31, 2025, on March 5, 2026. The company will conduct two webcasts, one in English and another in Chinese, to discuss these results with analysts and investors. The webcasts will allow for Q&A sessions and will be accessible via the company's website. A replay of the presentations will be provided shortly after the events.
Read more →HCMHUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet - First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplifi
HUTCHMED announced that the Phase III trial results of savolitinib and osimertinib were published in The Lancet, confirming significant efficacy in treating advanced non-small cell lung cancer (NSCLC) with MET amplification. The combination therapy demonstrated substantial improvements in progression-free survival compared to chemotherapy, with a median of 8.2 months. Regulatory approval for this treatment was granted in China in June 2025. The results highlight a new strategy in addressing resistance mechanisms in EGFR-mutated NSCLC patients.
Read more →HCM▲ +6.6%on this news
HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China - Delivers rapid, durable responses in wAIHA, the more c
HUTCHMED has reported positive topline results from the Phase III portion of the ESLIM-02 trial for its drug sovleplenib, targeting warm antibody autoimmune hemolytic anemia (wAIHA). The study, conducted in China, met its primary endpoint by demonstrating a durable hemoglobin response in treated patients. This investigational treatment may represent a significant advance for patients with limited options after failing standard therapies. The full study results will be presented at an upcoming scientific conference, with plans for a New Drug Application submission to the China NMPA in the first half of 2026.
Read more →HCMHUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Na ve Pancreatic Ductal Adenocarcinoma Hong Kong, Shanghai & Florham Park, NJ - Monda
HUTCHMED has commenced the Phase III stage of its clinical trial investigating a combination treatment for metastatic pancreatic ductal adenocarcinoma (PDAC). This trial will evaluate the efficacy and safety of surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine against standard treatment. Enrollment aims to expand the trial to approximately 400 additional patients following initial promising results in the Phase II segment, which demonstrated better progression-free survival rates with the experimental regimen. However, PDAC retains a notably low survival rate, highlighting the urgency of effective treatments.
Read more →HCMTotal Voting Rights Hong Kong, Shanghai & Florham Park, NJ - Wednesday
HUTCHMED (China) Limited reported that as of December 31, 2025, its issued share capital consists of 872,327,620 ordinary shares, each carrying one voting right. This information serves as a basis for existing shareholders to determine their notification obligations under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. The total number of ordinary shares is also equivalent to depositary interests traded on AIM and American depositary shares on Nasdaq. The notice includes contact details for investor and media enquiries.
Read more →HCMHUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification - NDA supported by positive Phase II registration s
HUTCHMED has announced the acceptance of its New Drug Application (NDA) for savolitinib in China, granted priority review by the NMPA. This application is supported by positive data from a Phase II study focusing on patients with MET-amplified gastric cancer. Savolitinib aims to be the first selective MET inhibitor available in China for this patient group, which has limited treatment options. The drug was previously designated as a Breakthrough Therapy by the NMPA in 2023, reflecting its potential in addressing a high-need area in cancer treatment.
Read more →HCMBlocklisting Six Monthly Return Hong Kong, Shanghai, & Florham Park, NJ - Monday
HUTCHMED (China) Limited announced its six-monthly blocklisting return covering the period from June 29, 2025, to December 28, 2025. The company reported static figures in terms of the block scheme, with no increases since the last return. During this period, a total of 216,150 ordinary shares were allotted under the 2015 HUTCHMED Share Option Scheme, leaving a balance of 45,775,868 shares available for issuance at the end of the reporting period. The total number of securities issued rose to 872,327,620.
Read more →HCMHUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors - First-in-human trial of candidate from the next-generation ATTC platform - - Simultaneous China and
HUTCHMED has commenced a global Phase I clinical trial for HMPL-A251, a novel PI3K/PIKK-HER2 antibody-targeted therapy conjugate aimed at treating patients with unresectable and advanced HER2-expressing solid tumors. The trial, which started with the first dose in China, will assess the safety, tolerability, and preliminary efficacy of HMPL-A251. This candidate represents a first-in-class approach designed to target pathways associated with cancer while minimizing systemic toxicity. The clinical development is part of HUTCHMED's strategy to leverage its next-generation ATTC platform for improved cancer therapies.
Read more →HCMHUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China Hong Kong, Shanghai & Florham Park, NJ - Monday
HUTCHMED has announced the continuation of coverage for its drugs ELUNATE, ORPATHYS, and SULANDA under China's updated National Reimbursement Drug List effective January 1, 2026. Additionally, TAZVERIK will be included in the inaugural National Commercial Health Insurance Innovative Drug List, enhancing patient access to cutting-edge treatments. This move reflects the Chinese government's commitment to improving drug affordability for its populace. The new reimbursement system aims to make high-cost innovative drugs more accessible through various insurance plans, thereby supporting the advancement of China's pharmaceutical industry.
Read more →HCMHUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting Hong Kong, Shanghai & Florham Park, NJ - Thursday
HUTCHMED has announced the presentation of new and updated clinical data at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting. Key findings include results from studies involving compounds such as HMPL-A83, fruquintinib, and surufatinib in relation to various cancers. Noteworthy presentations include first-in-human results and ongoing studies of fruquintinib in renal cell carcinoma and pancreatic cancer treatments. The event will highlight the potential advancements in cancer therapies developed by HUTCHMED.
Read more →HCMHUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS and TAGRISSO Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression
HUTCHMED has announced the completion of patient enrollment for the SAFFRON Phase III trial, which investigates the combination of ORPATHYS and TAGRISSO as a treatment for patients with advanced non-small cell lung cancer (NSCLC) after progression on TAGRISSO. This trial aims to provide a chemotherapy-free, all-oral treatment option for patients exhibiting MET overexpression and/or amplification. The study involves 338 patients from over 230 sites across 29 countries, with topline results anticipated in the first half of 2026. If results are favorable, they could pave the way for global regulatory submissions for this combination therapy.
Read more →HCMHUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event - HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action -
HUTCHMED has announced significant advancements in its research and development pipeline during an R&D Updates event. Key highlights include the introduction of the innovative Antibody-Targeted Therapy Conjugate (ATTC) platform and progress on the lead candidate HMPL-A251, which demonstrates promising preclinical efficacy. The company is advancing its late-stage pipeline with ongoing clinical trials and plans to initiate clinical development for HMPL-A251 by late 2025. HUTCHMED's strategy aims to address critical needs in oncology and immunology through its novel therapies.
Read more →HCMHUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - First investigational drug candidate using the HUTCHMED ATTC techno
HUTCHMED has announced promising preclinical data for HMPL-A251, the first investigational drug from its Antibody-Targeted Therapy Conjugate (ATTC) platform, at the AACR-NCI-EORTC Conference. This first-in-class therapy targets HER2-positive cancers and has shown significant antitumor activity across various tumor cell lines while demonstrating a low toxicity profile. The company aims to begin global clinical trials for HMPL-A251 by the end of 2025, potentially transforming the treatment landscape for HER2-associated malignancies. The data highlights HMPL-A251's dual-action mechanism that synergistically leverages HER2 targeting and PAM pathway inhibition.
Read more →HCMVesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ - Tuesday, October 2 1 , 2025: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performan
HUTCHMED (China) Limited has announced the vesting of non-performance based awards under its Long Term Incentive Plan (LTIP) to several managerial personnel on October 20, 2025. The awards, originally granted on October 20, 2021, include 1,938 American depositary shares for Dr. Dan Eldar, Ms. Edith Shih, and Professor Tony Mok. This transaction is in compliance with the UK Market Abuse Regulation and demonstrates the company's commitment to its managerial staff's long-term incentives.
Read more →HCMHUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress - The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell
HUTCHMED announced that data from the Phase III FRUSICA-2 registration trial for the fruquintinib and sintilimab combination will be presented at the 2025 ESMO Congress. The trial demonstrated significant improvements in progression-free survival (PFS) for patients with advanced renal cell carcinoma compared to existing monotherapy options. The data supports a New Drug Application review in China for this combination treatment, with potential implications for second-line treatment strategies in renal cell carcinoma. Overall, the study indicates a promising new direction for patients who have not responded well to previous treatments.
Read more →HCMHUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025 Hong Kong, Shanghai & Florham Park, NJ - Thursday
HUTCHMED has announced the presentation of new and updated clinical data at the upcoming ESMO Congress 2025. The data will include results from the FRUSICA-2 registration study assessing the combination of fruquintinib and sintilimab for treating advanced renal cell carcinoma, among other studies focusing on colorectal and lung cancers. These presentations reflect HUTCHMED’s commitment to advancing oncology treatments and highlight the relevance of their products in critical therapeutic areas.
Read more →HCMTotal Voting Rights Hong Kong, Shanghai & Florham Park, NJ - Tuesday
HUTCHMED (China) Limited has announced its total voting rights as of September 30, 2025. The company reports an issued share capital of 872,148,995 ordinary shares, each carrying one voting right. This figure is crucial for shareholders to determine if they must notify changes in their interest in HUTCHMED shares, as per the Financial Conduct Authority's guidelines. The press release clarifies that these shares are equivalent to depositary interests traded on AIM and American depositary shares on Nasdaq.
Read more →HCM▲ +9.5%on this news
Save the Date: HUTCHMED to Present R&D Updates on
HUTCHMED has announced an upcoming Research & Development update scheduled for October 31, 2025. The event will take place in Shanghai and will also be available via webcast, allowing for remote participation. Dr. Michael Shi, the company's Chief Medical Officer, will present insights into HUTCHMED's R&D strategy and updates on its antibody targeted therapy conjugates platform, including the lead candidate, HMPL-A251. Attendance at the in-person event is limited to invited guests.
Read more →HCM▲ +7.6%on this news
HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025 Hong Kong, Shanghai & Florham Park, NJ - Friday
HUTCHMED (HCM) announced that multiple clinical studies will be presented at the forthcoming 2025 World Conference on Lung Cancer and the CSCO Annual Meeting in September 2025. Among the highlights is the presentation of new data on savolitinib, a MET tyrosine kinase inhibitor, in treating non-small cell lung cancer. Additional data from other studies and the introduction of HMPL-653 will also be shared, reflecting HUTCHMED's ongoing commitment to advancing cancer therapies. The company maintains collaborative efforts with AstraZeneca for the development and commercialization of savolitinib.
Read more →HCMHong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly d
HUTCHMED (China) Limited has announced the appointment of Mr. Johnny Cheng as Acting Chief Executive Officer following Dr. Weiguo Su's temporary leave for health reasons. Mr. Cheng, who is also the Chief Financial Officer, will manage day-to-day operations while Dr. Su continues his role as Chief Scientific Officer. The Board supports both leaders and maintains confidence that the company's ongoing research and development efforts will remain unaffected during this transition.
Read more →HCMHUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS and TAGRISSO Combination as a First-Line Therapy for Certain Lung Cancer Patients in China Hong Kong, Shanghai & Florham Park, NJ
HUTCHMED has completed patient enrollment for the SANOVO Phase III trial, which is investigating the combination of ORPATHYS and TAGRISSO as a first-line therapy for certain non-small cell lung cancer (NSCLC) patients in China. The study will assess the efficacy and safety of this combination compared to TAGRISSO alone. Results from this study are expected in the latter half of 2026, with the potential for regulatory submissions if favorable outcomes are observed. ORPATHYS is a selective MET TKI, while TAGRISSO is a third-generation EGFR TKI, both promising advancements in treating this patient population.
Read more →HCM▼ -9%on this news
HUTCHMED Reports 2025 Interim Results - Indications expansion driving growth and ATTC platform enriching pipeline - - $455 million in net income attributable to HUTCHMED driven by non-core partial disposal - Hong Kong, S
HUTCHMED has released its interim results for the first half of 2025, reporting a net income of $455 million primarily due to a non-core partial disposal. The company highlighted the promising developments from its ATTC platform and the approval of ORPATHYS in China, indicating potential for future growth. However, it also experienced a decrease in total in-market sales by 4% and a significant drop in consolidated revenue by 22%, largely attributed to competitive pressures. Looking ahead, HUTCHMED anticipates improved sales growth in the latter half of 2025 through indication expansion and enhanced market strategies.
Read more →HCMHUTCHMED to Announce 2025 Half-Year Financial Results Hong Kong, Shanghai & Florham Park, NJ - Thursday
HUTCHMED (China) Limited announced that it will disclose its interim financial results for the first half of 2025 on August 7, 2025. The announcement includes details about subsequent webcasts designed for analysts and investors, with separate sessions in English and Chinese. The live presentations will be available through the company's website, allowing for real-time access to the information.
Read more →HCMUpdate on Joint Corporate Brokers in London Hong Kong, Shanghai & Florham Park, NJ - Wednesday , July 2 , 2025: HUTCHMED (China) Limited (" HUTCHMED ") (Nasdaq/AIM:HCM; HKEX:13) today announces that it has appointed Deut
HUTCHMED (China) Limited has appointed Deutsche Bank AG as its new joint Corporate Broker in London, replacing HSBC Bank plc. Panmure Liberum Limited and Cavendish Capital Markets Limited will continue to serve as joint Corporate Brokers. Additionally, Panmure Liberum will remain the Nominated Advisor for compliance with AIM regulations. This change marks a strategic shift in HUTCHMED's corporate brokerage structure.
Read more →HCMGrant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, June 10 , 202 5 : HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasda
HUTCHMED (China) Limited announced the grant of share options and LTIP awards aimed at attracting and retaining talent. The decision follows a compensation benchmarking study and involves Performance Targets essential for the exercise of these options. Dr. Weiguo Su received a substantial grant of share options, while additional LTIP awards were given to 132 employees. These grants are subject to performance measurements over the next few years, highlighting a commitment to performance-driven incentives despite inherent risks.
Read more →HCMHUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma Hong Kong, Shanghai & Florham Park, NJ - Thursd
HUTCHMED and Innovent announced the acceptance of their New Drug Application (NDA) in China for the fruquintinib and sintilimab combination therapy aimed at treating advanced renal cell carcinoma. This follows the promising results from the FRUSICA-2 clinical trial, where the therapy met its primary endpoint of progression-free survival. Both companies are committed to addressing the significant unmet need for patients who have failed first-line treatments. The combination therapy also demonstrated improvements in secondary endpoints and has received prior conditional approval for another indication.
Read more →HCMHUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting - The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significant PFS benefit wit
HUTCHMED announced positive results from the SACHI Phase III study at the 2025 ASCO Annual Meeting, showing that the combination of savolitinib and osimertinib provides significant progression-free survival (PFS) benefits for patients with EGFR mutation-positive NSCLC and MET amplification. The combination demonstrated a median PFS of 8.2 months compared to 4.5 months with chemotherapy. Additionally, the safety profile was favorable, with no new adverse events reported. The company also indicated plans for regulatory approval based on these promising results.
Read more →HCMTotal Voting Rights Hong Kong, Shanghai & Florham Park, NJ - Friday
HUTCHMED (China) Limited has notified the market of its total voting rights as of May 30, 2025. The issued share capital comprises 871,611,095 ordinary shares, each entitling one vote, with no treasury shares. This figure provides a basis for shareholders to determine their obligations under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. The ordinary shares are convertible to depositary interests or American depositary shares for trading on AIM and Nasdaq, respectively.
Read more →HCMHUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting Hong Kong, Shanghai & Florham Park, NJ - Friday
HUTCHMED (HCM) announces the presentation of significant clinical data at the ASCO Annual Meeting scheduled for May 30 - June 3, 2025. Key findings include promising results for savolitinib in NSCLC patients with MET amplification and noteworthy efficacy from ranosidenib in advanced solid tumors. Additionally, fruquintinib showcases meaningful outcomes in advanced endometrial cancer patients. The data highlights the progress and potential of HUTCHMED's therapeutic compounds in oncology.
Read more →HCM▼ -5.6%on this news
Annual General Meeting held on
On May 13, 2025, HUTCHMED (China) Limited held its Annual General Meeting where all proposed resolutions were successfully passed. A significant majority of shareholders voted in favor of key ordinary resolutions, including the re-election of directors and the appointment of auditors. The successful passage of all resolutions, including mandates related to share issuance and repurchase, reflects strong shareholder support and confidence in the company's governance.
Read more →HCMHUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025 Hong Kong, Shanghai & Florham Park, NJ - Thursday
HUTCHMED (China) Limited announced that it will present new and updated data at the upcoming AACR Annual Meeting 2025. The presentations will focus on various studies related to compounds developed by HUTCHMED, including savolitinib, fruquintinib, and surufatinib. Notable presentations include the combination of savolitinib with TAGRISSO, which has shown promising results in treating patients with advanced non-small cell lung cancer. The meeting will take place from April 25-30, 2025, in Chicago, Illinois.
Read more →HCM▲ +12.3%on this newsshared move
HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China Hong Kong, Shanghai & Florham Park, NJ - Tuesday
HUTCHMED has completed enrollment for its Phase II registration study of savolitinib in gastric cancer patients with MET amplification. The trial showed promising interim results, notably a 45% objective response rate. Regulatory approval is being pursued with Breakthrough Therapy Designation granted by NMPA. However, the study also reported instances of serious adverse events requiring monitoring as the study progresses.
Read more →HCM▼ -15.6%on this news
2024 Annual Report and Notice of Annual
HUTCHMED (China) Limited has announced the release of its 2024 Annual Report and Notice of Annual General Meeting (AGM), which will be posted to shareholders on April 8, 2025. The AGM is scheduled for May 13, 2025, and will be conducted as an electronic/hybrid meeting. This event highlights HUTCHMED's ongoing commitment to engaging with shareholders and its focus on the development of targeted therapies for cancer and immunological diseases.
Read more →HCMExtraordinary General Meeting held on
HUTCHMED (China) Limited successfully held its Extraordinary General Meeting on March 31, 2025. The primary resolution regarding the sale and purchase of a 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited was approved by shareholders, receiving 99.9745% votes in favor. This outcome indicates a solid consensus among shareholders about the company's strategic direction.
Read more →HCM▼ -7.1%on this news
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma - First and only EZH2 inhibitor approved by the NMPA - -HUTCHMED's fo
HUTCHMED has received conditional approval from the NMPA for TAZVERIK (tazemetostat) to treat adult patients with relapsed or refractory follicular lymphoma (FL) with EZH2 mutation, following the completion of a bridging study. This approval represents HUTCHMED's first foray into hematological malignancies and is a significant milestone, as TAZVERIK is the first EZH2 inhibitor to be sanctioned in China. The approval was based on positive clinical trial results, and further studies will follow to confirm efficacy and safety.
Read more →HCMHUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 - SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO i
HUTCHMED has highlighted results from the SAVANNAH Phase II trial demonstrating the efficacy of savolitinib combined with TAGRISSO in treating advanced non-small cell lung cancer (NSCLC) with MET overexpression. This combination exhibited a notable objective response rate of 56% and provided encouraging results in overall survival for patients with MET exon 14 mutations. Additionally, the drug's safety profile remained consistent with prior studies, indicating it is a viable treatment option without new safety concerns. The company also plans to present more data at the European Lung Cancer Congress 2025.
Read more →HCM▲ +8.2%on this newsshared move
HUTCHMED Reports 2024 Full Year Results and Provides Business Updates 65% oncology products revenue growth drove profitable operation and supported new ATTC platform Hong Kong, Shanghai & Florham Park, NJ - Wednesday
HUTCHMED reported its financial results for the year ending December 31, 2024, highlighting a 65% growth in oncology product revenues. The successful commercialization of FRUZAQLA and the positive performance of its new ATTC platform significantly contributed to the company's profitability. However, sales for ORPATHYS remained flat, reflecting increased competition in the market. The company is poised for further growth with global expansion of its medicines and strategic developments in its pipeline.
Read more →HCM▲ +8.2%on this newsshared move
HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China Hong Kong, Shan
HUTCHMED and Innovent have announced that their FRUSICA-2 Phase II/III study assessing fruquintinib and sintilimab for advanced renal cell carcinoma (RCC) met its primary endpoint for progression-free survival. This promising combination has received conditional approval for another indication and shows potential as a treatment option for patients who have not adequately responded to previous therapies. Co-leading investigators emphasized the significance of these results in addressing unmet medical needs in this patient population. The detailed findings from the study will be presented at an upcoming scientific conference.
Read more →HCMVesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ - Fri day, March 14 , 202 5 : HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performanc
HUTCHMED (China) Limited has announced the vesting of non-performance based awards under its Long Term Incentive Plan for Dr. Weiguo Su, the company's Chief Executive Officer. On March 13, 2025, he was vested with 19,913 American depositary shares. This announcement complies with UK Market Abuse Regulation requirements and marks an important milestone in the company's compensation structure for key executives.
Read more →HCMNotice of Extraordinary General Meeting Hong Kong, Shanghai, & Florham Park, NJ - Thursday
HUTCHMED (China) Limited has announced that it will hold an Extraordinary General Meeting (EGM) on March 31, 2025, to seek shareholder approval for the proposed disposal of its 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited. The meeting will be accessible both in-person in Hong Kong and online. Shareholders will receive the EGM materials on March 14, 2025, and are encouraged to review them thoroughly ahead of the meeting.
Read more →HCMHUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China Hong Kong, Shanghai & Florham Park, NJ - Thursda
HUTCHMED has completed enrollment for a Phase II registration study of fanregratinib (HMPL-453) targeting intrahepatic cholangiocarcinoma in patients with FGFR2 fusion/rearrangement. The study, which enrolled 87 patients, will evaluate the drug's efficacy and safety, with primary and secondary endpoints focusing on response rates and survival outcomes. Topline results are expected by the end of 2025, which could lead to a New Drug Application submission if favorable. HUTCHMED holds all rights to fanregratinib globally.
Read more →HCMHUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee Hong Kong, Shanghai & Florham Park, NJ - Wednesday
HUTCHMED (China) Limited has appointed Mr. Wong Tak Wai as an Independent Non-executive Director and member of the Audit Committee, effective March 6, 2025. Mr. Wong has over 35 years of experience in accounting and corporate finance, with a notable past role at PricewaterhouseCoopers. The company views his expertise as beneficial for its strategic growth. His appointment is subject to review and renewal at the next annual general meeting.
Read more →HCMOverseas Regulatory Announcement - Update on Transaction HUTCHMED (China) Limited ("HUTCHMED") notes the below text, which is from an announcement released to the Stock Exchange of Hong Kong Limited on
HUTCHMED (China) Limited has provided an update regarding its proposed divestment of a 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited. The transaction involves the sale of shares to GP Health Service Capital, including designated third-party purchasers. The aggregate purchase price for the shares is estimated at USD 339.7 million, and carries conditions regarding profit compensation guarantees over the next several years. The announcement further details the expected timeline for communications with shareholders.
Read more →HCM▲ +8.1%on this news
HUTCHMED to Announce 2024 Final Results Hong Kong, Shanghai & Florham Park, NJ - Wednesday
HUTCHMED (China) Limited will announce its final results for 2024 on March 19, 2025. A conference call and audio webcast will follow the announcement, allowing investors and analysts to engage with management. Additionally, a Chinese-language webcast will be held, highlighting the company's commitment to accessibility for diverse stakeholders.
Read more →HCMOverseas Regulatory Announcement - Disposal Transaction HUTCHMED (China) Limited (" HUTCHMED ") notes the below text, which is from an announcement released to the Stock Exchange of Hong Kong Limited on
HUTCHMED (China) Limited announced a delay in dispatching a circular regarding its proposed disposal of a 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited. Originally expected to be sent by January 28, 2025, the dispatch has been postponed to on or before February 28, 2025, due to additional time required by the GP Purchaser Fund amidst the Chinese New Year holidays. The completion of the disposal is contingent upon several conditions being met, which may affect its execution.
Read more →HCMHUTCHMED Announces NMPA Full Approval for ORPATHYS (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC - Indication expands to include treatment-na ve patients - - The 2021 condition
HUTCHMED has announced full approval from the NMPA for ORPATHYS (savolitinib) in China, now including treatment-naive patients with advanced or metastatic NSCLC featuring MET exon 14 skipping alterations. This approval converts the previous conditional authorization from 2021 into a full license, significantly broadening its indication. The decision follows positive results from a Phase IIIb clinical trial showcasing strong efficacy and an acceptable safety profile for both treatment-naive and previously treated populations. HUTCHMED aims to further advance research and increase access to ORPATHYS for NSCLC patients.
Read more →HCMHUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture - HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to
HUTCHMED has announced a divestment of its 45% interest in Shanghai Hutchison Pharmaceuticals Limited for approximately US$608 million. This move is part of the company's strategy to focus on its core business of developing innovative cancer therapies. The proceeds from this sale will be directed towards advancing HUTCHMED's internal pipeline, particularly its antibody-targeted therapy conjugates, with clinical trials expected to start in the second half of 2025. The transaction is expected to close by the end of Q1 2025, pending shareholder and regulatory approvals.
Read more →HCMAppointment of Cavendish as Joint Corporate Broker in London Hong Kong, Shanghai & Florham Park, NJ - Tuesday
HUTCHMED (China) Limited has announced the appointment of Cavendish Capital Markets Limited as its new joint Corporate Broker in London, effective January 1, 2025. This strategic addition complements the existing roles of Panmure Liberum Limited and HSBC Bank plc, who will continue their involvement as joint brokers. The move aims to strengthen HUTCHMED's presence in the London market and comply with AIM rules through its nominated advisor.
Read more →HCMBlocklisting Six Monthly Return Hong Kong, Shanghai & Florham Park, NJ - Monday
HUTCHMED (China) Limited has released its six-monthly return regarding the 2015 Share Option Scheme. This report, covering the period from June 29 to December 28, 2024, shows that the company has issued 241,375 shares under the scheme with a remaining balance of 46,502,393 shares available for allocation. No increase in the block scheme has been reported since the last return. The total number of securities in issue at the end of this period is 871,601,095.
Read more →HCMHUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA (fruquintinib) - US$10 million milestone payment to HUTCHMED follows first national reimbursement in Eur
HUTCHMED has announced it will receive a US$10 million milestone payment from Takeda following the first national reimbursement recommendation for its drug FRUZAQLA (fruquintinib) in Europe, specifically in Spain. This milestone comes after the drug was approved by the European Commission in June 2024 for patients with metastatic colorectal cancer. The partnership with Takeda aims to improve access for CRC patients in Europe, emphasizing the significance of FRUZAQLA's introduction to the market as an innovative treatment.
Read more →HCMHUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS and TAGRISSO Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy Hong Kong, Shanghai & F
HUTCHMED has received Breakthrough Therapy Designation from China's NMPA for its combination therapy of ORPATHYS and TAGRISSO, targeted at lung cancer patients with MET amplification after prior EGFR inhibitor treatment. The ongoing Phase III SACHI trial assesses the efficacy and safety of this combination against traditional chemotherapy in advanced NSCLC patients. Breakthrough designation suggests an expedited development process, addressing significant unmet medical needs in this cancer population.
Read more →HCMHUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE (Fruquintinib) in Combination with TYVYT (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - First regulato
HUTCHMED and Innovent announced that the NMPA in China has granted conditional approval for the combination of ELUNATE (fruquintinib) with TYVYT (sintilimab) for treating advanced endometrial cancer in patients with pMMR tumors. This marks the initial regulatory approval for a fruquintinib combination therapy with an immune checkpoint inhibitor. The decision follows positive data from the Phase II FRUSICA-1 study, which demonstrated significant response and survival rates. Both companies aim to enhance treatment options for patients who have limited responses to traditional therapies.
Read more →HCM▼ -8%on this newsshared move
HUTCHMED Announces Continued Inclusion of ORPATHYS (savolitinib) in the National Reimbursement Drug List in China at Current Terms Hong Kong, Shanghai & Florham Park, NJ - Thursday
HUTCHMED has announced that ORPATHYS (savolitinib) will remain on China's National Reimbursement Drug List (NRDL) under the same terms as its current agreement. This inclusion, effective from January 1, 2025, supports the affordability of this innovative treatment for non-small cell lung cancer patients with specific mutations. ORPATHYS is jointly developed by HUTCHMED and AstraZeneca, and it is the first selective MET TKI approved in China. The continued inclusion in the NRDL reflects the government's efforts to enhance access to cancer therapies for the public.
Read more →HCMHUTCHMED Announces Launch by Takeda of FRUZAQLA (fruquintinib) in Japan - Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 - - Milestone payment to be made to HUT
HUTCHMED announced the launch of FRUZAQLA (fruquintinib) in Japan by Takeda, following its approval by the Japanese Ministry of Health, Labour and Welfare. This milestone marks the first new oral targeted therapy for metastatic colorectal cancer (CRC) approved in Japan in over a decade. The launch comes after successful results from the Phase III FRESCO-2 trial and will provide a much-needed treatment option in a market with high unmet medical needs. HUTCHMED is set to receive a milestone payment from Takeda, demonstrating the value of their ongoing partnership.
Read more →HCMHUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress Hong Kong, Shanghai & Florham Park, NJ - Wedne sday, November 6 , 2024: HUTCHMED (China) Limi
HUTCHMED announced that new data from the ESLIM-01 Phase III trial of sovleplenib will be presented at the 2024 ASH Annual Meeting and ESMO Asia Congress. The data indicates long-term efficacy in treating chronic primary immune thrombocytopenia, with 81% of patients responding to treatment. The results will feature during multiple presentations at the conferences, showcasing promising findings on the treatment's safety and effectiveness. Additionally, various investigator-initiated studies from HUTCHMED will also be presented.
Read more →HCM▼ -5%on this news
Total Voting Rights Hong Kong, Shanghai, & Florham Park, NJ - Thursday
HUTCHMED (China) Limited has announced its total voting rights as of October 31, 2024. The company reports an issued share capital of 871,561,945 ordinary shares, each carrying one voting right. Shareholders can use this figure to assess their required notifications under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. The company also provides details on the equivalence of its ordinary shares with depositary interests and American depositary shares.
Read more →HCMVesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ - Mon day, October 2 1 , 2024: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performan
HUTCHMED (China) Limited announced that awards under its Long Term Incentive Plan were vested on October 20, 2024, for several key managerial personnel. The awards pertain to non-performance-based grants made on October 20, 2021. The vested awards included a total of 1,938 American depositary shares for each Non-Executive Director involved. This event aligns with regulatory requirements of the UK Market Abuse Regulation.
Read more →HCM▲ +5.3%on this newsshared move
HUTCHMED Announces that TAGRISSO plus ORPATHYS demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial - New d
HUTCHMED has announced promising results from the SAVANNAH Phase II trial, showcasing the efficacy of the treatment combination of TAGRISSO and ORPATHYS in lung cancer patients with MET overexpression or amplification. The trial indicated a high, clinically meaningful response rate for patients whose tumors progressed following treatment with TAGRISSO. Further, the results emphasize the potential of this combination therapy to combat MET-driven resistance in EGFR-mutated non-small cell lung cancer. These findings will be shared with global regulatory authorities and presented at an upcoming medical meeting.
Read more →HCM▲ +5.2%on this news· ran to +15% by day 3
HUTCHMED Announces Japan Approval for FRUZAQLA (fruquintinib) Received by Takeda - Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer - - Fruqu
HUTCHMED has announced that its partner Takeda has received approval from the Japanese Ministry of Health for FRUZAQLA (fruquintinib) to treat previously treated metastatic colorectal cancer. This marks a significant development as FRUZAQLA is the first novel treatment for this condition approved in Japan in over ten years. The approval is based on the results from the Phase III FRESCO-2 trial, which demonstrated significant improvements in patient survival. Fruquintinib has also been approved in the US and Europe, showcasing its potential as an effective treatment option for colorectal cancer.
Read more →HCMHUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer Hong Kong, Shanghai & Florham Park, NJ - Monday
HUTCHMED (China) Limited has announced that new clinical data will be presented at the upcoming 2024 ESMO Congress and the World Conference on Lung Cancer. The data includes results from the FLOWERS study, showcasing the efficacy of osimertinib combined with savolitinib for non-small cell lung cancer patients. Preliminary findings indicate improved response and disease control rates compared to monotherapy. Additionally, further analysis of fruquintinib's studies in colorectal and gastric cancers will be discussed at the ESMO Congress.
Read more →HCMTotal Voting Rights Hong Kong, Shanghai, & Florham Park, NJ - Friday
HUTCHMED (China) Limited has announced its total voting rights as of August 30, 2024, revealing an issued share capital of 871,469,720 ordinary shares. This disclosure is in line with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, which assists shareholders in determining their interest notifications. The announcement includes equivalency information regarding depositary interests and American depositary shares on trading platforms. No shares are held in treasury.
Read more →HCMTR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying
HUTCHMED (China) Limited has reported a major shareholder notification indicating a decrease in voting rights held by CA Fern Parent from 4.81% to 3.54%. This change was communicated following a notification on August 21, 2024, after reaching the threshold on August 20, 2024. The notification outlines the current holdings and the descending percentage of voting rights tied to the shares. The Carlyle Group, which controls the shareholder, does not hold any beneficial interest in the underlying securities.
Read more →HCMHUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia Hong Kong, Shanghai & Florham Park, NJ - Wedne sday, August 21 , 2024: HUTCHMED (China) Limited (" HUTCHMED ") (Nasdaq/AIM:HCM; HKEX:13) today
HUTCHMED is set to host a physician expert call on August 28, 2024, to discuss the treatment landscape of immune thrombocytopenia (ITP). The call will be conducted in Chinese and aims to inform investors of HUTCHMED's recent advancements. Sovleplenib, HUTCHMED's investigational drug for ITP, has shown effective results in Phase III trials. However, the drug has yet to receive regulatory approval, and there are inherent risks in its further development.
Read more →HCMGrant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan Hong Kong, Shanghai, & Florham Park, NJ: Tuesday , August 6 , 2024: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasda
HUTCHMED (China) Limited announced the grant of share options and long-term incentive plan awards aimed at attracting and retaining top talent. On August 5, 2024, the company granted 1,405,767 share options to CEO Dr. Weiguo Su, with performance targets set for the financial years 2024 to 2026. Additional non-performance-related share options and cash awards were also granted to other executive directors and employees. The company has a clawback policy in place to recover compensation in the event of financial misstatements. Overall, these grants are part of HUTCHMED's strategy to align executive compensation with the company’s performance and objectives.
Read more →HCM▲ +8%on this newsshared move
HUTCHMED Reports 2024 Interim Results and Provides Business Updates Hong Kong, Shanghai & Florham Park, NJ - Wednesday
HUTCHMED (HCM) announced its 2024 interim results for the first half of the year, highlighting significant revenue growth in its oncology products, particularly a 59% rise compared to the previous year. The company reported a collaborative success with Takeda and emphasized its ongoing commitment to clinical developments and sustainable practices. Notably, while oncology product sales increased substantially, total revenue saw a decline of 43%. Regulatory milestones for new drug applications are anticipated in the coming months, signaling potential future growth.
Read more →HCM▲ +5.4%on this news
HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status Hong Kong, Shanghai & Florham Park, NJ - Thurs day, Ju
HUTCHMED has announced that its New Drug Application (NDA) for tazemetostat, a treatment for relapsed or refractory follicular lymphoma, has been accepted for review by the China National Medical Products Administration (NMPA), with Priority Review status granted. This milestone follows tazemetostat's approvals in other regions, including the U.S. and Japan. The NDA submission is backed by results from a Phase II bridging study in China and other clinical studies. HUTCHMED continues to collaborate with Epizyme to bring this treatment to market in China and surrounding areas.
Read more →HCMBlocklisting Six Monthly Return Hong Kong, Shanghai, & Florham Park, NJ - Friday
HUTCHMED (China) Limited announced its blocklisting six monthly return for the period from December 29, 2023, to June 28, 2024. The 2015 HUTCHMED Share Option Scheme continues to have a remaining balance of 46,743,768 ordinary shares not yet issued. During the reporting period, 103,450 shares were allotted under the scheme. The total number of ordinary shares issued at the end of the period stands at 871,359,720.
Read more →HCMHUTCHMED to Announce 2024 Half-Year Financial Results Hong Kong, Shanghai & Florham Park, NJ - Wednesday
HUTCHMED (China) Limited will announce its interim financial results for the first half of 2024 on July 31, 2024. The announcement will be followed by a conference call and audio webcast, allowing analysts and investors to engage with HUTCHMED management. The call will have both English and Chinese language options, catering to a diverse audience. Live and recorded versions of the call will be accessible via the company’s website.
Read more →HCMHUTCHMED Announces European Commission Approval for FRUZAQLA (fruquintinib) Received by Takeda - Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Tri
HUTCHMED has announced the European Commission's approval of FRUZAQLA (fruquintinib) for the treatment of previously treated metastatic colorectal cancer, marking a significant advancement in oncology. This therapy, developed by HUTCHMED and Takeda, is notable for being the first targeted treatment in the EU for colorectal cancer in over a decade. The approval is based on positive results from the Phase III FRESCO-2 trial, which demonstrated meaningful improvements in patient survival outcomes. FRUZAQLA is expected to address the high unmet needs of patients in Europe, offering a new treatment option for those ineligible for current therapies.
Read more →HCMHUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology - Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo - - Presentations at EHA
HUTCHMED announced the publication of results from its Phase III ESLIM-01 trial of sovleplenib, a treatment for primary immune thrombocytopenia (ITP), in The Lancet Haematology. The trial demonstrated a durable response rate of 48.4% compared to 0% with the placebo, showing significant promise for patients with prior treatments. The findings were also shared at the 2024 European Hematology Association congress, supporting the ongoing regulatory submission process in China. The safety profile of the treatment was found to be tolerable, indicating a potential new option for those suffering from ITP.
Read more →HCMHUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine Updated subgroup efficacy and quality of life data were also presented on June 1 at ASCO 2024 Hong Kong, Shanghai & Florham Pa
HUTCHMED announced that Phase III trial results for fruquintinib, combined with paclitaxel, were published in Nature Medicine. The study demonstrated a statistically significant improvement in progression-free survival for patients with second-line advanced gastric cancer. Quality of life metrics remained stable, indicating no adverse effects from the treatment. However, while the study highlighted potential benefits, the overall survival improvement did not reach statistical significance.
Read more →HCMHUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China Hong Kong, Shanghai & Florham Park, NJ - Fri day, June 7 , 2024: HUTCHMED (China) Limited ("
HUTCHMED has initiated a Phase I clinical trial for HMPL-506, a menin inhibitor targeting hematological malignancies, particularly acute myeloid leukemia (AML). The trial began with the first patient dosing occurring on May 31, 2024, and aims to evaluate the safety and efficacy of the drug in at least 60 patients across multiple centers in China. This investigation comes at a critical time, as current treatment options for AML patients with specific genetic mutations are limited, and HMPL-506 represents a novel therapeutic approach.
Read more →HCMHUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting Hong Kong, Shanghai & Florham Park, NJ - Friday
HUTCHMED is set to present new data at the 2024 ASCO Annual Meeting, including promising results from the Phase II study of fruquintinib combined with sintilimab for advanced endometrial cancer. The combination treatment demonstrated notable efficacy with a disease control rate of 88.5% and median progression-free survival of 9.5 months. Additional updates on other studies, including those involving gastric and colorectal cancer, are also anticipated. The data presentation could bolster HUTCHMED's market presence in targeted cancer therapies.
Read more →HCMHUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress Hong Kong, Shanghai & Florham Park, NJ - Friday , May 17
HUTCHMED announced its participation in the upcoming EHA2024 Congress where it will present topline results from the ESLIM-01 Phase III study of Sovleplenib and data on investigational therapies targeting hematological malignancies. The Phase III trial showcased a notable 48.4% durable platelet response in primary immune thrombocytopenia patients, compared to zero in the placebo group, coupled with a rapid median response time of 1.1 weeks. Additionally, data from the Phase II part of ESLIM-02 demonstrated positive outcomes for patients with warm antibody autoimmune hemolytic anemia. The presentations highlight HUTCHMED's advancements in hematological treatment options.
Read more →HCMAnnual General Meeting held on May 1 0 , 202 4 - Poll Results Hong Kong, Shanghai, & Florham Park, NJ: Friday, May 1 0 , 202 4 : HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM; HKEX:13) today ann
HUTCHMED (China) Limited held its Annual General Meeting on May 10, 2024, where shareholders passed all ordinary and special resolutions. Notable outcomes included the adoption of audited financial statements for the year ended December 31, 2023, and the re-election of multiple directors with significant majority votes. Additionally, the company renewed its commitment to its auditors, signaling a commitment to compliant financial practices and governance.
Read more →HCMHUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Na ve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui - Almost half a million people dia
HUTCHMED has launched a Phase II/III clinical trial to assess the efficacy of combining surufatinib and camrelizumab with standard chemotherapy for metastatic pancreatic ductal adenocarcinoma (PDAC). This collaboration with Hengrui aims to exploit the synergistic effects of immunotherapy and chemotherapy in treating this aggressive cancer, which has a very low survival rate. The trial is set to enroll up to 500 patients, with overall survival as the primary endpoint. Initial data suggests that this combination may outperform traditional chemotherapy treatments.
Read more →HCMHUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda - If approved in the European Union, fruquintinib will be the first novel targeted therapy f
HUTCHMED's partner Takeda has received a positive opinion from the EMA's CHMP for fruquintinib, a novel therapy for previously treated metastatic colorectal cancer. If approved, fruquintinib will be the first selective VEGFR inhibitor available in the EU for this condition, marking a significant advancement in treatment options. The positive opinion is based on results from the Phase III FRESCO-2 clinical trial, which showed promising overall and progression-free survival outcomes. The European Commission's decision on marketing authorization is pending.
Read more →HCMVesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ - Monday
HUTCHMED (China) Limited announced the vesting of non-performance based awards granted under its Long Term Incentive Plan (LTIP) on April 20, 2024. Noteworthy executives, including those in managerial roles, received substantial allocations of American depositary shares (ADS). This event aligns with regulatory compliance requirements, ensuring transparency in executive compensation. The awards reflect HUTCHMED's ongoing commitment to incentivizing its leadership team.
Read more →HCM2023 Annual Report and Notice of Annual General Meeting
HUTCHMED (China) Limited has announced the posting of its 2023 Annual Report and Notice of Annual General Meeting (AGM) for shareholders. The AGM is scheduled for May 10, 2024, to be held both in-person and online, which reflects the company's adaptive strategies. HUTCHMED emphasizes its focus on developing targeted therapies and immunotherapies for cancer and immunological diseases. The company continues to expand its global presence with marketed medicines in China and the U.S.
Read more →HCMHUTCHMED Highlights Data to be Presented at AACR Congress 202 4 Hong Kong, Shanghai & Florham Park, NJ - Friday , April 5 , 2024: HUTCHMED (China) Limited (" HUTCHMED ") (Nasdaq/AIM:HCM; HKEX:13) today anno
HUTCHMED (China) Limited recently announced that new data from several studies will be presented at the AACR Annual Meeting 2024. Notable findings include promising preclinical results for HMPL-506, a menin-MLL inhibitor, which showed stronger inhibitory potency in leukemia models and better synergy with other treatments. Additionally, HMPL-A067, an antibody-drug conjugate, outperformed daratumumab in preclinical models of B-cell malignancies. This highlights HUTCHMED's commitment to advancing its pipeline of innovative cancer therapies ahead of planned clinical trials.
Read more →HCMHUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status - NDA accepted and bo
HUTCHMED and Innovent have announced the acceptance of their New Drug Application for the combination of fruquintinib and sintilimab to treat advanced endometrial cancer in China. This combination has received priority review status from the China National Medical Products Administration following its designation as a Breakthrough Therapy. The decision is supported by Phase II trial data demonstrating positive results in patients who have not responded to prior systemic therapy. This development marks a significant step forward in enhancing treatment options for endometrial cancer patients in China.
Read more →HCMHUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Na ve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC - Oral presentation at the European Lung Cancer
HUTCHMED has announced that the supplemental New Drug Application (sNDA) for its drug, savolitinib, has been accepted by China's National Medical Products Administration (NMPA). This acceptance relates to the treatment of adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) featuring MET exon 14 alterations. If approved, the new indication will expand its use from previously treated patients to include treatment-naive patients as well, potentially increasing the drug's market reach following its conditional approval in 2021. Clinical trial data indicates promising efficacy and safety profiles for savolitinib in both treatment-naive and previously treated populations.
Read more →HCMHUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China Hong Kong, Shanghai & Florham Park, NJ - Friday , March 22 , 20
HUTCHMED has announced the initiation of the registration stage for the ESLIM-02 Phase II/III trial of sovleplenib, targeting warm antibody autoimmune hemolytic anemia (wAIHA) in China. Following positive results from the initial Phase II trial and consultations with the NMPA, the company is advancing its investigational treatment, with 21 patients already enrolled and plans to include approximately 90 more. This study aims to confirm the safety and efficacy of sovleplenib, a selective small molecule inhibitor targeting Syk, crucial in autoimmune responses.
Read more →HCM▼ -9.6%on this news
Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan Hong Kong, Shanghai, & Florham Park, NJ: Thursday , March 14 , 2024: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasd
HUTCHMED (China) Limited announced the grant of share options and Long Term Incentive Plan Awards on March 14, 2024. Share options were awarded to Dr. Weiguo Su, the CEO, contingent on meeting specific performance targets over the financial years 2023 to 2025. Additionally, a cash award of $500,000 was granted to Dr. Su under the LTIP, emphasizing the company's focus on attracting and retaining talent.
Read more →HCM▼ -8.5%on this news
Vesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ - Tuesday
HUTCHMED (China) Limited announced the vesting of awards under its Long Term Incentive Plan for executives Dr. Weiguo Su and Mr. Johnny Cheng, totaling 108,686 American depositary shares. This vesting occurred following the company's 2023 annual results announcement on February 28, 2024. Dr. Su received 93,545 ADS while Mr. Cheng received 15,141 ADS. These awards were granted on March 26, 2021, and vesting underscores management's performance recognition.
Read more →HCMHUTCHMED Reports 2023 Full Year Results and Provides Business Updates Revenue grew 97% (102% CER) to US$838 million, with net income of US$101 million First U.S. FDA approval of our self-developed medicine, FRUZAQLA (fru
HUTCHMED reported significant financial growth in 2023, with revenues increasing by 97% to US$838 million and a net income of US$101 million. The company achieved its first U.S. FDA approval for FRUZAQLA, boosting its market presence. Additionally, HUTCHMED's collaboration with Takeda has strengthened its financial position, enabling further expansion in both China and international markets. The company remains focused on maintaining an upward trajectory in revenue and advancing its pipeline of medicines.
Read more →HCMHUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session Hong Kong, Shanghai & Florham Park, NJ - Wednesday
HUTCHMED presented data from its Phase III FRUTIGA trial on fruquintinib for second-line treatment of advanced gastric cancer at the ASCO Plenary Series. The trial results indicated a statistically significant improvement in progression-free survival with the combination of fruquintinib and paclitaxel compared to paclitaxel alone. Although there was an improvement in overall survival, it did not meet statistical significance. The results may position fruquintinib as a promising option for patients who have failed prior therapies, supporting its further development.
Read more →HCMHUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership Hong Kong, Shanghai & Florham Park, NJ - Friday
HUTCHMED announced that Inmagene has exercised options to license drug candidates IMG-007 and IMG-004 as part of their ongoing strategic partnership initiated in 2021. Inmagene will now have exclusive rights to develop, manufacture, and commercialize the drugs globally. The collaboration holds potential milestone and royalty payments for HUTCHMED based on the success of these candidates in treating immunological diseases. Clinical development for both candidates is currently in progress, with IMG-007 in Phase IIa trials and IMG-004 having completed a Phase I study.
Read more →HCMHUTCHMED to Announce 2023 Final Results Hong Kong, Shanghai & Florham Park, NJ - Thursday
HUTCHMED (China) Limited is set to announce its final results for the year ending December 31, 2023, on February 28, 2024. The announcement will be followed by a management conference call and audio webcast, allowing investors and analysts to engage directly with HUTCHMED's management. Both English and Chinese webcasts will be available, enhancing participation from diverse audiences. The details about the conference call will be provided in the financial results announcement.
Read more →HCMHUTCHMED Receives ELUNATE (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer - First medicine approved under new "1+" mechanism by HKSAR Government, providing an im
HUTCHMED has received marketing approval for its drug ELUNATE (fruquintinib) in Hong Kong, targeting patients with previously treated metastatic colorectal cancer. This makes it the first medicine to be approved under Hong Kong's new "1+" registration mechanism. Fruquintinib is already approved in mainland China, Macau, and the U.S., presenting a promising option for patients facing severe treatment limitations. The approval underscores HUTCHMED's commitment to enhancing patient access to innovative therapies.
Read more →HCMHUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status - NDA accepted and granted Priority Review following its Breakthro
HUTCHMED has announced that its New Drug Application (NDA) for sovleplenib, intended for the treatment of adult primary immune thrombocytopenia (ITP), has been accepted by the China National Medical Products Administration and granted Priority Review status. This development follows the successful Phase III ESLIM-01 trial, which demonstrated a significant increase in durable response rates in treated patients compared to those on placebo. The NDA illustrates HUTCHMED's commitment to addressing an unmet need for effective treatments in ITP, a condition marked by the immunologic destruction of platelets. Sovleplenib is a selective oral inhibitor targeting spleen tyrosine kinase (Syk), which is crucial for managing hematological disorders.
Read more →HCMHUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China Hong Kong, Shanghai & Florham Park, NJ -
HUTCHMED has announced the completion of patient enrollment for its Phase II/III trial of fruquintinib combined with sintilimab as a treatment for advanced renal cell carcinoma in China. This randomized, open-label study aims to evaluate the treatment's efficacy and safety against existing monotherapies. A total of 234 patients have been enrolled, with topline results expected by the end of 2024, which may pave the way for a New Drug Application to Chinese regulators. The study is led by prominent investigators from major Chinese hospitals.
Read more →HCMHUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses Hong Kong, Shanghai & Florham Park, NJ - Friday
HUTCHMED announced that it will present vital clinical data on its investigational drugs, including fruquintinib and HMPL-295, at the upcoming ESMO Asia and ESMO Immuno-Oncology Congresses. The studies focus on advanced cancers and indicate encouraging results, particularly for patients with cervical cancer and non-small cell lung cancer. These presentations aim to substantiate the drugs' safety and efficacy profiles, contributing to ongoing development efforts. The company continues to advance its research in these critical areas of oncology.
Read more →HCM▼ -7.2%on this news
HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA (fruquintinib) for Previously Treated Metastatic Colorectal Cancer - FRUZAQLA is the first targeted therapy approved in the U.S. for metastatic colore
HUTCHMED announced that its partner Takeda has received U.S. FDA approval for FRUZAQLA (fruquintinib), an oral targeted therapy for previously treated metastatic colorectal cancer. This approval marks a significant breakthrough as it is the first targeted therapy in this space in over ten years. The drug is designed to improve patient survival and quality of life, backed by successful Phase III trial data. HUTCHMED will also benefit financially from the approval through a $35 million milestone payment and ongoing royalties on sales.
Read more →HCMHUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023 Hong Kong, Shanghai & Florham Park, NJ - Monday
HUTCHMED has announced that it will showcase new and updated clinical data on fruquintinib at the ESMO Congress 2023. Presentations will cover its efficacy in combination with various therapies for advanced gastric, colorectal, and non-small cell lung cancers. The company anticipates further developments and regulatory approvals for fruquintinib in multiple international markets. The ongoing evaluation of fruquintinib’s effectiveness and safety in combination treatments remains crucial.
Read more →HCMDirector's Share Dealing Hong Kong, Shanghai & Florham Park, NJ - Thursday
HUTCHMED (China) Limited announced that Mrs. Debbie Sue Chung, spouse of Independent Non-executive Director Mr. Graeme Jack, sold 3,000 American Depositary Shares (ADSs) at a price of $14.70 per ADS on September 12, 2023. Following this transaction, Mr. Jack retains a total of 17,339 ADSs, equivalent to approximately 0.01% of the company's issued share capital. This sale was disclosed in compliance with the EU Market Abuse Regulation and is noted as initial notification of the transaction.
Read more →HCMHUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China Hong Kong, Shanghai & Florham Park, NJ - Tuesday
HUTCHMED has completed patient enrollment for a Phase II bridging study of tazemetostat, aimed at treating patients with relapsed/refractory follicular lymphoma in China. The study will assess the drug's efficacy, safety, and pharmacokinetics, focusing on patients with EZH2 mutations. Tazemetostat, already FDA-approved for certain conditions, offers hope for improved therapeutic options in this patient demographic. HUTCHMED's collaboration with Ipsen allows for further exploration and development of tazemetostat's clinical applications.
Read more →HCM▲ +7.2%on this newsshared move
HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer Hong Kong, Shanghai & Florham Park, NJ - Tuesday
HUTCHMED has announced that its drug savolitinib has received Breakthrough Therapy Designation from China's NMPA for the treatment of advanced gastric cancer with MET amplification. This designation is significant as it may expedite the drug's review and approval process in China. The Phase II registration study shows promising results, with a reported objective response rate of between 45% and 50% among patients. Savolitinib is seen as a vital option for patients who have not responded to other treatments, addressing a critical unmet need in gastric cancer care.
Read more →HCMHUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China - Randomized, double-blind, controlled trial met primary endpoint of durable response
HUTCHMED announced positive results from the Phase III ESLIM-01 trial of sovleplenib for treating primary immune thrombocytopenia (ITP) in China. The trial met its primary endpoint, indicating a durable response rate, along with all secondary endpoints. The National Medical Products Administration of China granted Breakthrough Therapy designation for sovleplenib, facilitating plans for a New Drug Application by the end of 2023. The ongoing investigation highlights the potential of sovleplenib as a new treatment option for patients with chronic ITP.
Read more →HCM▼ -15.8%on this news
Exercise of Share Options by a Director Hong Kong, Shanghai & Florham Park, NJ - Monday
Hutchmed (China) Limited announced that Dr. Weiguo Su exercised share options resulting in the issuance of 3,000,000 ordinary shares at an exercise price of GBP1.97 each. This transaction increases Dr. Su's shareholding to 5,000,000 ordinary shares and 632,505 American Depositary Shares, representing 0.94% of the company's current share capital. The announcement is in compliance with the EU Market Abuse Regulation, highlighting executive management's involvement in share performance. Such transactions underscore ongoing executive confidence in the company's future direction.
Read more →HCMHUTCHMED Reports 2023 Interim Results and Provides Business Updates Strong execution on strategic direction, delivering near-term value while charting a path for growth, exemplified by global partnership with Takeda Reve
HUTCHMED reported a successful first half of 2023 with a revenue increase of 164% to $533 million, largely attributed to a partnership with Takeda for the licensing of fruquintinib. The company aims to achieve self-sustainability by 2025 and has several ongoing clinical trials with more than 15 studies in progress across its drug pipeline. Executive remarks emphasized successful navigation of market challenges and significant growth in both commercial and R&D activities. The FDA Priority Review for fruquintinib is scheduled for November 30 this year.
Read more →HCMHUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study Hong Kon
HUTCHMED has received Breakthrough Therapy Designation from the NMPA in China for the combination of fruquintinib and sintilimab, aimed at treating advanced endometrial cancer in patients with pMMR tumors. The enrollment for a multi-center registration study is now complete, evaluating the combination's efficacy and safety. Positive results could lead to submission for regulatory approval in the first half of 2024, highlighting the significance of this treatment for patients with limited options after platinum-based therapies. Fruquintinib, already approved for use in colorectal cancer, continues to show promise in various cancer indications.
Read more →HCMHUTCHMED Announces Changes to Board of Directors and Technical Committee Ms Ling Yang to replace Mr Lefei Sun as Non-executive Director; Professor Solange Peters appointed as Special Advisor to the Technical Committee Ho
HUTCHMED announced leadership changes on July 13, 2023, appointing Ms. Ling Yang as a Non-executive Director, replacing Mr. Lefei Sun. Ms. Yang comes with significant experience in biotechnology management and healthcare investments, expected to strengthen the company's board. Additionally, Professor Solange Peters has been appointed as a Special Advisor to the Technical Committee, focusing on oncology and immunology research. Both appointments are viewed positively by the board as contributive to the strategic direction of HUTCHMED.
Read more →HCMHUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China Hong Kong, Shanghai & Florham Park, NJ - Monday
HUTCHMED has announced the initiation of a Phase I clinical study in China for HMPL-415, a selective allosteric inhibitor targeting SHP2, with the first patient dosing occurring on July 6, 2023. This multi-center, open-label trial will evaluate HMPL-415's safety and preliminary efficacy in patients with advanced malignant solid tumors, with plans to enroll approximately 80 participants. Key investigators leading the study include Dr. Tianshu Liu and Dr. Nong Yang. HUTCHMED retains global rights to HMPL-415, but a series of risks associated with clinical trials and regulatory approvals exist.
Read more →HCMBlocklisting Six Monthly Return Hong Kong, Shanghai, & Florham Park, NJ - Thursday
HUTCHMED (China) Limited has released its blocklisting six monthly return for the period from December 29, 2022, to June 28, 2023. The report includes details about the Share Option Schemes adopted in 2005 and 2015, including the number of securities issued and the balances remaining under each scheme. For the 2005 scheme, 449,250 shares were allotted, leaving a balance of 434,050 shares, while the 2015 scheme saw 936,860 shares allotted, with a remaining balance of 51,730,718 shares. Overall, HUTCHMED has a total of 866,161,450 shares issued as of the end of the reporting period.
Read more →HCMHUTCHMED to Announce 2023 Half-Year Financial Results Hong Kong, Shanghai & Florham Park, NJ - Monday
HUTCHMED (China) Limited will announce its interim financial results for the first half of 2023 on July 31, 2023. The announcement will be followed by a conference call and audio webcast presentation for analysts and investors. The presentation will be available for downloading before the conference call, with additional details to be provided in the announcement. A replay will also be accessible via the company website.
Read more →HCM▲ +8.2%on this news
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency - Application Includes Data fr
Takeda and HUTCHMED announced the validation of their marketing authorization application for fruquintinib by the European Medicines Agency. The drug is aimed at treating previously treated metastatic colorectal cancer and has demonstrated superior efficacy in clinical trials. Fruquintinib, a selective VEGFR inhibitor, shows promise in improving patient outcomes, particularly in a cancer market with limited treatment options. If approved, it will be the first highly selective option for this indication available in the EU.
Read more →HCMHUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings Hong Kong, Shanghai & Florham Park, NJ - Friday
HUTCHMED has announced the presentation of new clinical data for two investigational hematological malignancy therapies, HMPL-306 and amdizalisib, at the upcoming EHA and ICML meetings. HMPL-306 is a dual inhibitor targeting mutant IDH1 and IDH2, while amdizalisib is a selective inhibitor of the PI3K-delta isoform. Early results show potential benefits for patients with relapsed/refractory myeloid malignancies and various subtypes of non-Hodgkin's lymphoma, though some safety concerns were noted.
Read more →HCMGrant of Awards under Long Term Incentive Plan and Share Options under Share Option Scheme Hong Kong, Shanghai, & Florham Park, NJ: Tuesday , June 6 , 2023: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 1
HUTCHMED (China) Limited announced the granting of long-term incentive awards and share options under its compensation plans, aimed at retaining key talent. On June 5, 2023, the company awarded conditional performance-related LTIP awards targeting financial year 2023, with vesting contingent upon achieving performance goals and continued employment. Additionally, share options were given to 68 employees at an exercise price of $12.51 per ADS, expected to vest over four years. HUTCHMED's practices follow an independent compensation benchmarking study to set competitive policies.
Read more →HCMTotal Voting Rights Hong Kong, Shanghai, & Florham Park, NJ - Wednesday
HUTCHMED (China) Limited announced that as of May 31, 2023, its issued share capital consists of 866,161,450 ordinary shares, all of which carry voting rights. This figure will assist shareholders in determining if they need to disclose any interest changes under market regulations. The announcement also outlines the equivalency of ordinary shares to depositary interests and American depositary shares traded on respective stock exchanges.
Read more →HCMHUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting Hong Kong, Shanghai & Florham Park, NJ - Thursday
HUTCHMED (HCM) will showcase new clinical data at the 2023 ASCO Annual Meeting, highlighting findings for its investigational therapies fruquintinib, surufatinib, and HMPL-453. Notable results from the FRESCO-2 study show fruquintinib improving overall and progression-free survival in metastatic colorectal cancer. Additionally, the presentation includes exploratory results on various combinations with other anti-cancer drugs. First-in-human data for HMPL-453 targeting FGFR alterations in intrahepatic cholangiocarcinoma is also significant, providing a new treatment avenue.
Read more →HCMHUTCHMED Announces Board of Directors and Board Committee Membership Hong Kong, Shanghai & Florham Park, NJ - Friday
HUTCHMED (China) Limited has announced the deferred appointments of Professor Solange Peters as an Independent Non-executive Director, a member of its Technical Committee, and the Audit Committee, initially set to take effect after the AGM on May 12, 2023. Additionally, Professor Mok Shu Kam, Tony is announced to join the Audit Committee, contingent on his re-election by shareholders. The delay in appointments is a key detail in this announcement, reflecting potential shifts in governance structure.
Read more →HCMHUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees Hong Kong, Shanghai & Florham Park, NJ - Wednesday
HUTCHMED (China) Limited has announced the appointment of Professor Solange Peters as an Independent Non-executive Director and member of the Technical and Audit Committees effective from May 12, 2023. Professor Peters, a recognized leader in oncology and immunology, has an extensive background, including serving as the youngest president of the European Society for Medical Oncology. The Board anticipates that her expertise will add considerable value to the company and assist in achieving its objectives. Her role includes a focus on innovative immunotherapy and biomarker discovery.
Read more →HCMVesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ - Friday
HUTCHMED (China) Limited announced the vesting of non-performance based awards under its Long Term Incentive Plan on April 20, 2023. The awards were granted to various managerial personnel, including Executive and Non-Executive Directors. Each relevant director received a specific number of American depositary shares (ADS) as part of this vesting process, which adheres to UK Market Abuse Regulation requirements. This event signifies the company's strategy to maintain leadership continuity and aligns with their long-term compensation goals.
Read more →HCMHUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer Hong Kong, Shanghai & Florham Park, NJ - Tuesday
HUTCHMED announced the acceptance of its New Drug Application for fruquintinib in China, aimed at treating second-line advanced gastric cancer. This decision by the China National Medical Products Administration supports the need for more effective treatments in a region with a high incidence of gastric cancer. The application is bolstered by data from the successful Phase III FRUTIGA trial, which showed positive results for this combination therapy. HUTCHMED is optimistic about addressing unmet medical needs with this new option for patients in China.
Read more →HCMHUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023 Hong Kong, Shanghai & Florham Park, NJ - Wednesday
HUTCHMED (China) Limited announced that it will present clinical and non-clinical data related to five of its investigational drug candidates during the American Association for Cancer Research Annual Meeting 2023. The presentations will feature promising data on savolitinib in patients with gastric cancer, as well as other targeted therapies for various malignancies. These studies include insights into how combinatory approaches may enhance treatment efficacy in challenging cancer types.
Read more →HCM▲ +5.9%on this news· ran to +21% by day 3shared move
Annual Report and Notice of Annual General Meeting Hong Kong, Shanghai, & Florham Park, NJ - Tuesday
HUTCHMED (China) Limited has announced the release of its 2022 Annual Report along with the Notice of Annual General Meeting. Shareholders who opted for printed materials will receive these documents starting April 12, 2023. The AGM is scheduled for May 12, 2023, and will take place in a hybrid format at Harbour Grand Kowloon in Hong Kong. This setup allows participation both in-person and online.
Read more →HCM▲ +5.9%on this news· ran to +21% by day 3shared move
SECURITIES AND EXCHANGE COMMISSION
Hutchmed (China) Limited submitted its report as a foreign private issuer to the SEC, adhering to SEC regulations under the Securities Exchange Act of 1934. The document includes essential details such as the commission file number and the address of its principal executive offices. This report covers activities for the month of April 2023 and features the company's annual report as an exhibit, signed by Chief Financial Officer Johnny Cheng.
Read more →HCM▲ +6.3%on this news· ran to +17% by day 3
HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations Hong Kong, Shanghai & Florham Park, NJ - Tuesday
HUTCHMED has commenced registration phase enrollments for HMPL-453 and savolitinib following consultations with the China National Medical Products Administration (NMPA). These trials target intrahepatic cholangiocarcinoma and gastric cancer patients, respectively, and are crucial for potential future New Drug Applications. The first patients in both studies received their doses in March 2023, with the studies expected to enroll additional patients in the coming months.
Read more →HCMHUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer - NDA supported by data from global Phase III FRESCO-2 study in the U.S
HUTCHMED has finalized the rolling submission of a New Drug Application for its cancer treatment fruquintinib to the U.S. FDA, supported by data from the global Phase III FRESCO-2 study. This submission represents a pivotal step for patients suffering from refractory metastatic colorectal cancer, supported by a noteworthy reduction in death risk as reported in clinical trials. Additionally, marketing authorization submissions for the drug in Europe and Japan are expected to be completed within the year. However, concerns remain regarding the observed adverse events associated with treatment and the uncertainty of receiving regulatory approval.
Read more →HCM▲ +7.3%on this news
HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China Hong Kong, Shanghai & Florham Park, NJ - Tuesday
HUTCHMED has completed the licensing agreement with Takeda for fruquintinib, which will be developed and commercialized outside of China. This deal includes an upfront payment of $400 million and potential milestone payments totaling up to $730 million. Fruquintinib is positioned as a promising option for patients with refractory metastatic colorectal cancer. Marketing submissions in major international markets are planned to be completed in 2023, with ongoing clinical implications dependent on regulatory reviews.
Read more →HCM▼ -17.9%on this news
Director's Share Dealing Hong Kong, Shanghai & Florham Park, NJ - Wednesday
HUTCHMED (China) Limited announced that Executive Director and CFO Johnny Cheng sold 1,300,000 ordinary shares at an average price of HK$27.073 on two occasions earlier this month. Following the sale, Cheng retains 1,261,460 shares and 274,493 American Depositary Shares (ADS). The transactions meet the disclosure requirements outlined by the EU Market Abuse Regulation. Concerns arise among investors regarding the implications of such a substantial share sale.
Read more →HCM▲ +5.3%on this news
HUTCHMED Reports 2022 Full Year Results and Provides Business Updates Landmark licensing deal with Takeda for fruquintinib outside of China, bringing HUTCHMED up to US$1.13 billion, plus royalties, and demonstrating exec
HUTCHMED reported its financial results for 2022, highlighting a landmark licensing agreement with Takeda for fruquintinib outside of China, potentially worth up to $1.13 billion. The company achieved a significant increase in oncology/immunology revenues, reporting a 37% rise to $163.8 million. Clinical success was noted with positive results for fruquintinib, which is now part of ongoing U.S. FDA submissions, and savolitinib, which is set to be included in the National Reimbursement Drug List. With a substantial cash balance bolstered by the Takeda deal, HUTCHMED is positioned well for a sustainable future.
Read more →HCMHUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China Hong Kong, Shanghai & Florham Park, NJ - Monday
HUTCHMED has announced the completion of patient enrollment for its Phase II registration trial of amdizalisib in patients with relapsed or refractory follicular lymphoma. The trial, conducted at over 35 sites in China, aims to evaluate the drug's efficacy and safety compared to existing treatment options. Topline results are anticipated in the latter half of 2023, with the potential to apply for marketing authorization depending on positive outcomes. Amdizalisib, a selective oral inhibitor targeting PI3K, may provide a beneficial profile for treating hematologic cancers.
Read more →HCMHUTCHMED to Announce 2022 Final Results Hong Kong, Shanghai & Florham Park, NJ - Tuesday
HUTCHMED (China) Limited will announce its final results for the year ended December 31, 2022, on February 28, 2023. The announcement will be followed by a conference call and audio webcast at 8:00 am EST, where management will present the results and answer questions from analysts and investors. The presentation will be accessible on the company's website prior to the call, and a replay will also be made available shortly after the event.
Read more →HCM▲ +5.9%on this news
HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China - HUTCHMED to receive US$400 million upfront on deal closing and up to US$730 million in potential future milestone payments, t
HUTCHMED has signed an exclusive licensing agreement with Takeda Pharmaceutical Company to develop and commercialize fruquintinib outside of China, Hong Kong, and Macau. The deal includes an upfront payment of $400 million and potential additional milestone payments up to $730 million, totaling up to $1.13 billion. Fruquintinib, a selective inhibitor for vascular endothelial growth factor receptors, has shown positive results in clinical trials for metastatic colorectal cancer. The companies plan to submit marketing authorizations in the U.S., Europe, and Japan in 2023.
Read more →HCMHUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS in the National Reimbursement Drug List in China Hong Kong, Shanghai & Florham Park, NJ -- Wednesday , J anu ary 18, 2023: HUTCHMED (China) Limited ("HUTCH
HUTCHMED announced that ORPATHYS (savolitinib) has been included in China's National Reimbursement Drug List following discussions with the NHSA. This decision, effective March 1, 2023, allows for broader access to this treatment for adults with advanced or metastatic non-small cell lung cancer with MET exon 14-skipping alterations. The inclusion is anticipated to improve treatment affordability and access for patients unable to tolerate standard chemotherapy. ORPATHYS has been recognized for its effectiveness since receiving conditional approval in 2021 and is expected to benefit many patients in need.
Read more →HCM▲ +10.8%on this news· ran to +23% by day 1
HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China Hong Kong, Shanghai & Florham Park, NJ - Tuesday
HUTCHMED has announced the completion of patient enrollment for the ESLIM-01 Phase III trial of sovleplenib, aimed at treating primary immune thrombocytopenia (ITP) in adults. The trial, which has enrolled 188 patients and began in October 2021, will evaluate efficacy and safety, with topline results expected in the second half of 2023. If results are positive, HUTCHMED plans to seek marketing authorization in China. Sovleplenib operates as a selective small molecule inhibitor targeting the spleen tyrosine kinase.
Read more →HCMHUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer - Company plans to complete rolling submission to the U.S. in the first half of 20
HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer - Company plans to complete rolling submission to the U.S. in the first half of 2023, followed by filings in Europe and Japan - - NDA is supported by glob
Read more →HCM▲ +5.1%on this news
HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals Reprioritization accelerating path to profitability Evaluation of partnership opportunities for select late-stage assets Hong Kong, Shangha
HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals Reprioritization accelerating path to profitability Evaluation of partnership opportunities for select late-stage assets Hong Kong, Shanghai & Florham Park, NJ - Tuesday, November 15, 2022: HUTCHM
Read more →HCM▲ +10.9%on this newsshared move
HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China - Results of dual primary endpoint study showed statistically significant and clinically meaningfu
HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China - Results of dual primary endpoint study showed statistically significant and clinically meaningful benefit in progression-free survival, a primary endpoint
Read more →HCMHUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China Hong Kong, Shanghai & Florham Park, NJ - Thursday , October 27 , 2022: HUTCH
HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China Hong Kong, Shanghai & Florham Park, NJ - Thursday, October 27, 2022: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces
Read more →HCMHUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China Hong Kong, Shanghai & Florham Park, NJ -- Monday
HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China Hong Kong, Shanghai & Florham Park, NJ -- Monday, October 10, 2022: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated
Read more →HCM▼ -7%on this news
Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan Hong Kong, Shanghai, & Florham Park, NJ: Wednesday , September 14 , 2022: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM;
Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, September 14, 2022: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) announces that on September 13, 2022, it granted
Read more →HCM▲ +5.6%on this newsshared move
HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of Fruquintinib in Refractory Metastatic Colorectal Cancer from the Upcoming ESMO 2022 Presentation - Fruquintinib treatment reduced the risk of deat
HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of Fruquintinib in Refractory Metastatic Colorectal Cancer from the Upcoming ESMO 2022 Presentation - Fruquintinib treatment reduced the risk of death by 34% in metastatic colorectal cancer (0.66 HR) - - Increased disease
Read more →HCMHUTCHMED Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022 - Trial met primary endpoint of overall survival and all secondary endpoints - - Selected as a late-bre
HUTCHMED Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022 - Trial met primary endpoint of overall survival and all secondary endpoints - - Selected as a late-breaker presentation - - Conference call and webcast to be held on Monday,
Read more →HCMInmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004 San Diego, Shanghai and Hong Kong - Tuesday
Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004 San Diego, Shanghai and Hong Kong - Tuesday, August 9, 2022: Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) announce today that the f
Read more →HCMHUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer - Trial met primary endpoint of overall survival and all secondary endpoints - - Overall s
HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer - Trial met primary endpoint of overall survival and all secondary endpoints - - Overall safety consistent with fruquintinib known profile - - Plan
Read more →HCM▼ -7.7%on this news
x200B; HUTCHMED Reports 2022 Interim Results and Provides Business Updates Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE ® , SULANDA ® and ORPATHYS ® growth ​ First presentat
0.190.14849283553729239181P2DP2DP2DP8Y0.25 HUTCHMED Reports 2022 Interim Results and Provides Business Updates Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE , SULANDA and ORPATHYS growth First presentation of SAVANNAH data showing 52% response rate and
Read more →HCM▼ -7.7%on this news
HUTCHMED Initiates a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China Hong Kong, Shanghai & Florham Park, NJ - Monday
HUTCHMED Initiates a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China Hong Kong, Shanghai & Florham Park, NJ - Monday, August 1, 2022: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that it has in
Read more →HCMHUTCHMED Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China - HMPL-A83 is the thirteenth innovative oncology drug candidate discovered i
HUTCHMED Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China - HMPL-A83 is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and its second large molecule drug candidate to enter
Read more →HCMHUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO at the 2022 WCLC Annual Meeting - 49% ORR amongst SAVANNAH patients with higher MET level
HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO at the 2022 WCLC Annual Meeting - 49% ORR amongst SAVANNAH patients with higher MET levels - Hong Kong, Shanghai & Florham Park, NJ - Wednesday, July 13, 2022: H
Read more →HCMInmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007 San Diego, Shanghai, Hong Kong and Sydney - Wednesday
Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007 San Diego, Shanghai, Hong Kong and Sydney - Wednesday, July 6, 2022: Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) announce today
Read more →HCM▼ -5.2%on this newsshared move
Blocklisting Six Monthly Return Hong Kong, Shanghai, & Florham Park, NJ - Wednesday
Blocklisting Six Monthly Return Hong Kong, Shanghai, & Florham Park, NJ - Wednesday, June 29, 2022: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return: 1. Name of applicant: HUTCHMED (China
Read more →HCMHUTCHMED to Announce 2022 Half-Year Financial Results Hong Kong, Shanghai & Florham Park, NJ - Monday
HUTCHMED to Announce 2022 Half-Year Financial Results Hong Kong, Shanghai & Florham Park, NJ - Monday, June 27, 2022: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2022 on Monday, August
Read more →HCM▼ -11.2%on this news
HUTCHMED Announces TAZVERIK Approved to be Used in Hainan Pilot Zone in China Hong Kong, Shanghai & Florham Park, NJ - Wednesday
HUTCHMED Announces TAZVERIK Approved to be Used in Hainan Pilot Zone in China Hong Kong, Shanghai & Florham Park, NJ - Wednesday, June 1, 2022: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that TAZVERIK (tazemetostat) has been approved by the
Read more →HCMGrant of Awards under Long Term Incentive Plan and Share Options under Share Option Scheme Hong Kong, Shanghai, & Florham Park, NJ: Tuesday , May 24 , 2022: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 1
Grant of Awards under Long Term Incentive Plan and Share Options under Share Option Scheme Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, May 24, 2022: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) announces that on May 23, 2022, it granted conditional awa
Read more →HCMAppointment of Non-Executive Director Hong Kong, Shanghai & Florham Park, NJ - Monday
Appointment of Non-Executive Director Hong Kong, Shanghai & Florham Park, NJ - Monday, May 16, 2022: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) announces that Mr Lefei Sun has been appointed as a Non-Executive Director with effect from May 16, 2022 and he wi
Read more →HCM▼ -7.3%on this news
Vesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ - Thursday
Vesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ - Thursday, April 21, 2022: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan ("L
Read more →HCMUpdate on Status under Holding Foreign Companies Accountable Act Hong Kong, Shanghai & Florham Park, NJ - Thursday
Update on Status under Holding Foreign Companies Accountable Act Hong Kong, Shanghai & Florham Park, NJ - Thursday, March 31, 2022: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM; SEHK:13) provides an update on its status under the Holding Foreign Compani
Read more →HCMAnnual Report and Notice of Annual General Meeting Hong Kong, Shanghai, & Florham Park, NJ - Wednesday
2021 Annual Report and Notice of Annual General Meeting Hong Kong, Shanghai, & Florham Park, NJ - Wednesday, March 23, 2022: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX:13) today announces that its 2021 Annual Report together with the Notice of Annual General Me
Read more →HCM▼ -7.5%on this news
Update on Status under Holding Foreign Companies Accountable Act Hong Kong, Shanghai & Florham Park, NJ - Friday
Update on Status under Holding Foreign Companies Accountable Act Hong Kong, Shanghai & Florham Park, NJ - Friday, March 11, 2022: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM; SEHK:13) would like to provide an update on its status under the Holding For
Read more →HCM▼ -13.3%on this newsshared move
HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS in Lung Cancer Hong Kong, Shanghai & Florham Park, NJ - Monday
HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS in Lung Cancer Hong Kong, Shanghai & Florham Park, NJ - Monday, March 7, 2022: ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that i
Read more →HCM▼ -6.9%on this news· ran to -31% by day 3shared move
HUTCHMED announces retirement of CEO and appointment of new CEO Hong Kong, Shanghai & Florham Park, NJ - Thursday
HUTCHMED announces retirement of CEO and appointment of new CEO Hong Kong, Shanghai & Florham Park, NJ - Thursday, March 3, 2022: ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM; HKEX: 13) today announces: Dr. Su has been selected and appointed to his additional role as the CEO
Read more →HCM▼ -6.9%on this news· ran to -31% by day 3shared move
HUTCHMED Reports 2021 Full Year Results and Provides Business Updates Oncology/Immunology revenues up 296% to $119.6 million, due to ELUNATE growth and the 2021 launches of SULANDA and ORPATHYS ; Positive SAVANNAH, CALYP
Reports 2021 Full Year Results and Provides Business Updates Oncology/Immunology revenues up 296% to $119.6 million, due to ELUNATE growth and the 2021 launches of SULANDA and ORPATHYS ; Positive SAVANNAH, CALYPSO and VIKTORY studies triggered five registration studies on ORP
Read more →HCMHUTCHMED Receives Approval to Commercialize ELUNATE in Macau - First homegrown innovative medicine approved in Macau based on China clinical data - Hong Kong, Shanghai & Florham Park, NJ -- Tuesday
HUTCHMED Receives Approval to Commercialize ELUNATE in Macau - First homegrown innovative medicine approved in Macau based on China clinical data - Hong Kong, Shanghai & Florham Park, NJ -- Tuesday, March 1, 2022: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13
Read more →HCMHUTCHMED to Announce 2021 Final Results Hong Kong, Shanghai & Florham Park, NJ - Monday
HUTCHMED to Announce 2021 Final Results Hong Kong, Shanghai & Florham Park, NJ - Monday, February 7, 2022: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2021 on Thursday, March 3, 2022 at 7:0
Read more →HCMHUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors in China Hong Kong, Shanghai & Florham Park, NJ - Friday
HUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors in China Hong Kong, Shanghai & Florham Park, NJ - Friday, February 4, 2022: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces
Read more →HCMHUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China Hong Kong, Shanghai & Florham Park, NJ -- Thursday
HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China Hong Kong, Shanghai & Florham Park, NJ -- Thursday, January 20, 2022: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it has ini
Read more →HCMHUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastrointestinal Cancers Symposium Hong Kong, Shanghai & Florham Park, NJ - Wednesday
HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastrointestinal Cancers Symposium Hong Kong, Shanghai & Florham Park, NJ - Wednesday, January 19, 2022: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that updated
Read more →HCMTR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft W o r d f o rm a t i f po ss i b l e ) i 1a. Identity of the issuer or
TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft W o r d f o rm a t i f po ss i b l e ) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting ri
Read more →HCMHUTCHMED Receives Break through Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombo cytopenia Hong Kong, Shanghai & Florham Park, NJ -- Wednesday
HUTCHMED Receives Break through Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombo cytopenia Hong Kong, Shanghai & Florham Park, NJ -- Wednesday, January 12, 2022: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces th
Read more →HCMHUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lymphoma in China - HMPL-760 is the eleventh innovative potential oncology drug candidate di
HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lymphoma in China - HMPL-760 is the eleventh innovative potential oncology drug candidate discovered in-house by HUTCHMED - - HMPL-760 is HUTCHMED's fifth candidate
Read more →HCMHUTCHMED Included in FTSE Russell Indexes Hong Kong, Shanghai & Florham Park, NJ - Monday
HUTCHMED Included in FTSE Russell Indexes Hong Kong, Shanghai & Florham Park, NJ - Monday, December 20, 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it has been included by FTSE Russell in the FTSE Global Equity Index Series ("GEIS")
Read more →HCMGrant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan Hong Kong, Shanghai, & Florham Park, NJ: Wednesday , December 15 , 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM;
Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, December 15, 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) announces that on December 14, 2021, it granted sh
Read more →HCMHUTCHMED Highlights HMPL-523 Clinical Data Presented at the 2021 ASH Annual Meeting Hong Kong, Shanghai & Florham Park, NJ - Tuesday
HUTCHMED Highlights HMPL-523 Clinical Data Presented at the 2021 ASH Annual Meeting Hong Kong, Shanghai & Florham Park, NJ - Tuesday, December 14, 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces new analyses on the ongoing studies of HMPL-52
Read more →HCMHUTCHMED Highlights Surufatinib and Toripalimab Combination Clinical Data being Presented at the ESMO Immuno-Oncology 2021 Meeting Hong Kong, Shanghai & Florham Park, NJ - Friday
HUTCHMED Highlights Surufatinib and Toripalimab Combination Clinical Data being Presented at the ESMO Immuno-Oncology 2021 Meeting Hong Kong, Shanghai & Florham Park, NJ - Friday, December 10, 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces
Read more →HCM▼ -8.3%on this news
HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer - Recruitment of 687 patients globally completed in fifteen months, ahead of sched
HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer - Recruitment of 687 patients globally completed in fifteen months, ahead of schedule - - FRESCO-2 primary objective is to confirm overall clinical benefi
Read more →HCMHUTCHMED Announces Agreement with NHSA for Continued Inclusion of ELUNATE and Addition of SULANDA in the National Reimbursement Drug List in China Hong Kong, Shanghai & Florham Park, NJ - Friday
HUTCHMED Announces Agreement with NHSA for Continued Inclusion of ELUNATE and Addition of SULANDA in the National Reimbursement Drug List in China Hong Kong, Shanghai & Florham Park, NJ - Friday, December 3, 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX:13)
Read more →HCMTotal Voting Rights Hong Kong, Shanghai, & Florham Park, NJ - Tuesday
Hong Kong, Shanghai, & Florham Park, NJ - Tuesday, November 30, 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at November 30, 2021, the issued share capital of HUTCHMED consisted of 864,460,700 ordinary shares of US$0.1
Read more →HCMHUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS and TAGRISSO Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy - Follows important findings
HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS and TAGRISSO Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy - Follows important findings from the TATTON1 study of the combination in EGFR inhibitor refractory l
Read more →HCMHUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeting Hong Kong, Shanghai & Florham Park, NJ - Monday
HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeting Hong Kong, Shanghai & Florham Park, NJ - Monday, November 8, 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that new analyses and updates on the ongoi
Read more →HCMHUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combination with PD-L1 Inhibitor IMFINZI in Patients with MET-Driven Advanced Papillary Renal Cell Carcinoma - Follows multi
HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combination with PD-L1 Inhibitor IMFINZI in Patients with MET-Driven Advanced Papillary Renal Cell Carcinoma - Follows multiple global studies of savolitinib in papillary renal cell carcinoma patie
Read more →HCMHUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thrombocytopenia in China Hong Kong, Shanghai & Florham Park, NJ -- Thursday
HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thrombocytopenia in China Hong Kong, Shanghai & Florham Park, NJ -- Thursday, October 28, 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiate
Read more →HCMGrant of Awards under Long Term Incentive Plan Hong Kong, Shanghai, & Florham Park, NJ: Wednesday , October 20 , 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) announces that on
Grant of Awards under Long Term Incentive Plan Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, October 20, 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) announces that on October 20, 2021, it granted conditional awards ("LTIP Awards") under the Long
Read more →HCMHUTCHMED Announces Closing of Divestment of Non-Core OTC Joint Venture Hong Kong, Shanghai & Florham Park, NJ -- Wednesday
HUTCHMED Announces Closing of Divestment of Non-Core OTC Joint Venture Hong Kong, Shanghai & Florham Park, NJ -- Wednesday, September 29, 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX:13) today announces that, further to its announcement in March 2021 and fo
Read more →HCMHUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA in Combination with TUOYI in the Treatment of Advanced Neuroendocrine Carcinoma in China Hong Kong, Shanghai & Florham Park, NJ - Tuesday
HUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA in Combination with TUOYI in the Treatment of Advanced Neuroendocrine Carcinoma in China Hong Kong, Shanghai & Florham Park, NJ - Tuesday, September 21, 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX
Read more →HCMHUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced Neuroendocrine Tumors - Following surufatinib launch in China in January 2021; NDA acceptance by the U.S. FDA for r
HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced Neuroendocrine Tumors - Following surufatinib launch in China in January 2021; NDA acceptance by the U.S. FDA for review in June 2021; and MAA validation by the EMA in July 2021 all for ad
Read more →HCMHUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma Hong Kong, Shanghai & Florham Park, NJ - Monday
HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma Hong Kong, Shanghai & Florham Park, NJ - Monday, September 13, 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 1
Read more →HCMHUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS and TAGRISSO Combination as a First-Line Therapy for Certain Lung Cancer Patients in China - Follows important findings from the SAVANNAH
HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS and TAGRISSO Combination as a First-Line Therapy for Certain Lung Cancer Patients in China - Follows important findings from the SAVANNAH study of this combination in lung cancer patients whose tumors harbor mu
Read more →HCM▼ -7.2%on this newsshared move
HUTCHMED Announces Selection of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs Hong Kong, Shanghai & Florham Park, NJ - Monday
HUTCHMED Announces Selection of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs Hong Kong, Shanghai & Florham Park, NJ - Monday, September 6, 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that the Comp
Read more →HCMGrant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan Hong Kong, Shanghai, & Florham Park, NJ: Thursday , September 2 , 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; H
Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan Hong Kong, Shanghai, & Florham Park, NJ: Thursday, September 2, 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) announces that on September 1, 2021, it granted sha
Read more →HCMHUTCHMED Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer or Advanced Endometrial Cancer Hong Kong, Shanghai & Florham Park, NJ - Thur
HUTCHMED Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer or Advanced Endometrial Cancer Hong Kong, Shanghai & Florham Park, NJ - Thursday, August 26, 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:
Read more →HCMHUTCHMED Selected as Constituent of Certain Hang Seng Indexes Hong Kong, Shanghai & Florham Park, NJ - Monday
HUTCHMED Selected as Constituent of Certain Hang Seng Indexes Hong Kong, Shanghai & Florham Park, NJ - Monday, August 23, 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that HUTCHMED has been selected as a constituent stock of several ind
Read more →HCMHUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK (tazemetostat) in Greater China Collaboration designed to accelerate global development and investigate TAZVERIK combinations wi
HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK (tazemetostat) in Greater China Collaboration designed to accelerate global development and investigate TAZVERIK combinations with HUTCHMED's novel oncology medicines portfolio Epizyme t
Read more →HCM▲ +14.7%on this newsshared move
x200B; HUTCHMED Reports 2021 Interim Results and Provides Business Updates ELUNATE ® in-market sales 1 rose 186%, reflecting impact of in-house sales force ​ Received 1 st approval in China for ORPATHYS ®
HUTCHMED Reports 2021 Interim Results and Provides Business Updates ELUNATE in-market sales1 rose 186%, reflecting impact of in-house sales force Received 1st approval in China for ORPATHYS and 2nd approval in China for SULANDA U.S. and E.U. applications for surufatinib both a
Read more →HCM▲ +14.7%on this newsshared move
HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS in Patients with MET Amplified Gastric Cancer - Follows multiple Phase II studies of ORPATHYS in Asia including VIKTORY, which reported an 50% ob
HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS in Patients with MET Amplified Gastric Cancer - Follows multiple Phase II studies of ORPATHYS in Asia including VIKTORY, which reported an 50% objective response rate (ORR) in gastric cancer patients whose tumors harbo
Read more →HCMHong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the " Stock Exchange ") and Hong Kong Securities Clearing Company Limited (" HKSCC ") take no responsibility for the contents of this ann
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and Hong Kong Securities Clearing Company Limited ("HKSCC") take no responsibility for the contents of this announcement, make no representation as to its accuracy or comple
Read more →HCMHUTCHMED's Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines Agency - EMA commences review of surufatinib for the treatment of advanced neuroendocrine tum
HUTCHMED's Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines Agency - EMA commences review of surufatinib for the treatment of advanced neuroendocrine tumors - - Expands potential global reach of surufatinib, in addition to Ch
Read more →HCMHUTCHMED Announces First Commercial Sale of ORPATHYS in China, Triggering a US$25 million Milestone Payment from AstraZeneca Hong Kong, Shanghai & Florham Park, NJ - Tuesday
HUTCHMED Announces First Commercial Sale of ORPATHYS in China, Triggering a US$25 million Milestone Payment from AstraZeneca Hong Kong, Shanghai & Florham Park, NJ - Tuesday, July 13, 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) announces the first com
Read more →HCMHUTCHMED Announces Full Exercise of the Over-allotment Option of the Global Offering Hong Kong, Shanghai, & Florham Park, NJ - Monday
HUTCHMED Announces Full Exercise of the Over-allotment Option of the Global Offering Kong, Shanghai, & Florham Park, NJ - Monday, July 12, 2021: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM, HKEX:13) today announces the full exercise of the over-allo
Read more →HCMHUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL-295 in Patients with Advanced Solid Tumors in China Hong Kong, Shanghai and Florham Park, NJ - Tuesday
HUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL-295 in Patients with Advanced Solid Tumors in China Hong Kong, Shanghai and Florham Park, NJ - Tuesday, July 6, 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) has initiated a Phase I study of
Read more →HCMU.S. FDA Accepts Filing of HUTCHMED's NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors - U.S. FDA has assigned a target action date of
U.S. FDA Accepts Filing of HUTCHMED's NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors - U.S. FDA has assigned a target action date of April 30, 2022 - - If approved, surufatinib would be HUTCHMED's first novel oncology drug marketed outside of China - H
Read more →HCMHUTCHMED Announces the Closing of the Global Offering and the Primary Listing in Hong Kong Hong Kong, Shanghai, & Florham Park, NJ - Wednesday
HUTCHMED Announces the Closing of the Global Offering and the Primary Listing in Hong Kong Hong Kong, Shanghai, & Florham Park, NJ - Wednesday, June 30, 2021: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM) today announces the listing of its ordinary
Read more →HCMBlocklisting Six Monthly Return Hong Kong, Shanghai, & Florham Park, NJ - Tuesday
Blocklisting Six Monthly Return Hong Kong, Shanghai, & Florham Park, NJ - Tuesday, June 29, 2021: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: HUTCHMED (China) Limited 2.
Read more →HCMHUTCHMED Announces Pricing of Global Offering Hong Kong, Shanghai, & Florham Park, NJ - Wednesday
HUTCHMED Announces Pricing of Global Offering Hong Kong, Shanghai, & Florham Park, NJ - Wednesday, June 23, 2021: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM) today announces the pricing of its global offering (the "Global Offering") of 104,000,000
Read more →HCMtitled "Unaudited First Quarter 2021 Financial Information", of our report on Form 6-K furnished to the SEC on
HUTCHMED (China) Limited Supplemental and Updated Disclosures We recently filed an application (the "Listing Application") with The Stock Exchange of Hong Kong Limited (the "Stock Exchange") in connection with a proposed listing (the "Listing") of our ordinary shares, par value
Read more →HCMHUTCHMED (China) Limited Condensed Consolidated Balance Sheets as of
HUTCHMED (China) Limited Condensed Consolidated Balance Sheets as of December 31, 2020 and March 31, 2021 F-2 Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2020 and 2021 F-3 Condensed Consolidated Statements of Comprehensive
Read more →HCMHUTCHMED Launches Hong Kong Initial Public Offering Hong Kong, Shanghai, & Florham Park, NJ - Friday
HUTCHMED Launches Hong Kong Initial Public Offering Kong, Shanghai, & Florham Park, NJ - Friday, June 18, 2021: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM) today announces the launch of its Hong Kong public offering (the "Hong Kong Public Offering"
Read more →HCMHUTCHMED Announces NMPA Approval of Surufatinib (Sulanda in China) for Advanced Pancreatic Neuroendocrine Tumors - Second New Drug Application ("NDA") approved for Sulanda in China - - The pivotal Phase III SANET-p trial
HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda in China) for Advanced Pancreatic Neuroendocrine Tumors - Second New Drug Application ("NDA") approved for Sulanda in China - - The pivotal Phase III SANET-p trial demonstrated surufatinib reduced risk of progression o
Read more →HCMHUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program - HUTCHMED will review these highlights as part of its company update audio call and webcast on Wednesday,
HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program - HUTCHMED will review these highlights as part of its company update audio call and webcast on Wednesday, May 26 at 9 a.m. EDT to discuss data disclosures, its PD-1/L1 combinatio
Read more →HCMSave the date: HUTCHMED to Host Company Update on R&D, Commercial and ASCO Data For Analysts and Investors - HUTCHMED will hold a webcast on Wednesday, May 26 at 8 a.m. EDT to provide updates on recent prog
Save the date: HUTCHMED to Host Company Update on R&D, Commercial and ASCO Data For Analysts and Investors - HUTCHMED will hold a webcast on Wednesday, May 26 at 8 a.m. EDT to provide updates on recent progress and upcoming milestones - Hong Kong, Shanghai & Florham Park, NJ -
Read more →HCMHUTCHMED to Attend Upcoming Investor Conferences Hong Kong, Shanghai & Florham Park, NJ - Friday
HUTCHMED to Attend Upcoming Investor Conferences Hong Kong, Shanghai & Florham Park, NJ - Friday, May 7, 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of HUTCHMED, will participate in a virtual fires
Read more →HCMChange of Company Name Hong Kong, Shanghai, & Florham Park, NJ - Tuesday
Change of Company Name Hong Kong, Shanghai, & Florham Park, NJ - Tuesday, May 4, 2021: HUTCHMED (China) Limited (Nasdaq/AIM: HCM), formerly known as Hutchison China MediTech Limited, announces that, further to its "Results of Annual General Meeting" announcement released on Wedn
Read more →HCMHUTCHMED Initiates Phase II Registration Study of HMPL-689 in Patients with Follicular Lymphoma and Marginal Zone Lymphoma in China - Single-arm study in ~180 patients, with ORR as primary endpoint - - Rela
HUTCHMED Initiates Phase II Registration Study of HMPL-689 in Patients with Follicular Lymphoma and Marginal Zone Lymphoma in China - Single-arm study in ~180 patients, with ORR as primary endpoint - - Relapsed/refractory FL and MZL constitute approximately 25% of all NHL - -
Read more →HCMResults of Annual General Meeting Hong Kong, Shanghai, & Florham Park, NJ: Wednesday
Results of Annual General Meeting Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, April 28, 2021: Hutchison China MediTech Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General
Read more →HCMVesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ: Friday
Vesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ: Friday, April 23, 2021: Hutchison China MediTech Limited ("HUTCHMED") (Nasdaq/AIM: HCM) announces that the non-performance based awards granted under the Long Term Incentive Plan ("LTIP"
Read more →HCMNotification of Dilution of Voting Rights Hong Kong, Shanghai, & Florham Park, NJ: Wednesday
Notification of Dilution of Voting Rights Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, April 14, 2021: Hutchison China MediTech Limited ("HUTCHMED") (Nasdaq/AIM: HCM) was notified that CK Hutchison Holdings Limited ("CK Hutchison") shareholding[1] in HUTCHMED remains unch
Read more →HCMNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION HUTCHMED Announces US$100 Milli
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION HUTCHMED Announces US$100 Million Equity Investment by Baring Private Equity Asia Hong Ko
Read more →HCMTotal Voting Rights Hong Kong, Shanghai, & Florham Park, NJ: Wednesday
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, March 31, 2021: Hutchison China MediTech Limited ("HUTCHMED") (AIM/Nasdaq: HCM) hereby notifies the market that as at March 31, 2021, the issued share capital of HUTCHMED consisted of 728,122,215 ordinary shares of US$0.10 each,
Read more →HCMHUTCHMED Initiates International Phase I Trials of IDH1/2 Dual Inhibitor in Patients with Advanced Solid Tumors or Hematological Malignancies - HMPL-306 is the sixth innovative oncology drug candidate disco
HUTCHMED Initiates International Phase I Trials of IDH1/2 Dual Inhibitor in Patients with Advanced Solid Tumors or Hematological Malignancies - HMPL-306 is the sixth innovative oncology drug candidate discovered in house by HUTCHMED to enter into global development - Hong Kong,
Read more →HCMAnnual Report and Notice of Annual General Meeting Hong Kong, Shanghai, & Florham Park, NJ: Friday
2020 Annual Report and Notice of Annual General Meeting Hong Kong, Shanghai, & Florham Park, NJ: Friday, March 26, 2021: Hutchison China MediTech Limited ("HUTCHMED") (Nasdaq/AIM: HCM) today announces that its 2020 Annual Report together with the Notice of Annual General Meeting
Read more →HCMHUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for US$169 Million - Allows focus on China and global clinical development and market launches of key Oncology/Immunology assets - Hong Kong, Shanghai & Flor
HUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for US$169 Million - Allows focus on China and global clinical development and market launches of key Oncology/Immunology assets - Hong Kong, Shanghai & Florham Park, NJ -- Wednesday, March 24, 2021: Hutchison Chin
Read more →HCMHUTCHMED Initiates a Phase Ib/II Trial of Surufatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors Hong Kong, Shanghai & Florham Park, NJ - Wednesday
HUTCHMED Initiates a Phase Ib/II Trial of Surufatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors Hong Kong, Shanghai & Florham Park, NJ - Wednesday, March 24, 2021: Hutchison China MediTech Limited ("HUTCHMED") (Nasdaq/AIM: HCM) has initiated a Phase
Read more →HCMVesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai, & Florham Park, NJ: Wednesday
Vesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, March 10, 2021: Hutchison China MediTech Limited ("HUTCHMED") (Nasdaq/AIM: HCM) announces that following the announcement of the 2020 annual results of HUTCHMED on March 4, 2
Read more →HCMHutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate Identity Company to Host Annual Results Call & Webcast Today at 1 p.m. GMT / 8 a.m. EST / 9 p.m. HKT Hon
Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate Identity Company to Host Annual Results Call & Webcast Today at 1 p.m. GMT / 8 a.m. EST / 9 p.m. HKT Hong Kong, Shanghai & Florham Park, NJ Thursday, March 4, 202
Read more →HCMChi-Med to Announce 2020 Final Results Hong Kong, Shanghai, & Florham Park, NJ: Wednesday
Chi-Med to Announce 2020 Final Results Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, February 3, 2021: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) will be announcing its final results for the year ended December 31, 2020 on Thursday, March 4, 2021 at 12:
Read more →HCMChi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC Hong Kong, Shanghai, & Florham Park, NJ: Thursday
Chi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC Hong Kong, Shanghai, & Florham Park, NJ: Thursday, January 14, 2021: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announces that the final analysis of savolitinib in Phase Ib TAT
Read more →HCMChi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases Hong Kong, Shanghai, San Diego & Florham Park, NJ: Monday
Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases Hong Kong, Shanghai, San Diego & Florham Park, NJ: Monday, January 11, 2021: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) an
Read more →HCMBlocklisting Six Monthly Return London: Thursday
Blocklisting Six Monthly Return London: Thursday, December 31, 2020: Hutchison China MediTech Limited ("Chi-Med" or the "Company") (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of schem
Read more →HCMChi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors - Company plans to complete rolling submission in the first half of 2021 - - The p
Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors - Company plans to complete rolling submission in the first half of 2021 - - The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of
Read more →HCMChi-Med to Present at the 39 th Annual JP Morgan Healthcare Conference Hong Kong, Shanghai, & Florham Park, NJ: Tuesday
Chi-Med to Present at the 39th Annual JP Morgan Healthcare Conference Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, December 22, 2020: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at
Read more →HCMGrant of Share Options under Share Option Scheme London: Tuesday, December 15, 20 20 : Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) announces that on
Grant of Share Options under Share Option Scheme London: Tuesday, December 15, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) announces that on December 14, 2020, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its
Read more →HCMTotal Voting Rights London: Monday
London: Monday, November 30, 2020: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) hereby notifies the market that as at November 30, 2020, the issued share capital of Chi-Med consisted of 727,702,215 ordinary shares of US$0.10 each, with each share carrying one ri
Read more →HCMNotification of Dilution of Voting Rights London: Friday
Notification of Dilution of Voting Rights London: Friday, November 27, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) was notified that CK Hutchison Holdings Limited ("CK Hutchison") shareholding[1] in Chi-Med remains unchanged, at 332,478,770 ordinary shar
Read more →HCMNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Chi-Med Announces US$100 Millio
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Chi-Med Announces US$100 Million Equity Investment by CPP Investments Hong Kong, Shanghai
Read more →HCMChi-Med Highlights HMPL-689 Clinical Data to be Presented at the 62 nd ASH Annual Meeting Hong Kong, Shanghai, & Florham Park, NJ: Thursday
Chi-Med Highlights HMPL-689 Clinical Data to be Presented at the 62nd ASH Annual Meeting Hong Kong, Shanghai, & Florham Park, NJ: Thursday, November 5, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announces that initial analysis of the first in huma
Read more →HCMChi-Med to Attend Upcoming Industry and Investor Virtual Conferences Hong Kong, Shanghai, & Florham Park, NJ: Friday
Chi-Med to Attend Upcoming Industry and Investor Virtual Conferences Hong Kong, Shanghai, & Florham Park, NJ: Friday, October 30, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announces that Mr. Christian Hogg, Chief Executive Officer of Chi-Med, wil
Read more →HCMTotal Voting Rights London: Friday
London: Friday, October 30, 2020: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) hereby notifies the market that as at October 30, 2020, the issued share capital of Chi-Med consisted of 711,025,545 ordinary shares of US$0.10 each, with each share carrying one righ
Read more →HCMTotal Voting Rights London: Wednesday
London: Wednesday, September 30, 2020: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) hereby notifies the market that as at September 30, 2020, the issued share capital of Chi-Med consisted of 710,785,545 ordinary shares of US$0.10 each, with each share carrying o
Read more →HCMChi-Med Highlights Surufatinib Phase III Results in Neuroendocrine Tumors at ESMO 2020 and Publications in The Lancet Oncology Phase III SANET-p demonstrated surufatinib reduces the risk of disease progress
Chi-Med Highlights Surufatinib Phase III Results in Neuroendocrine Tumors at ESMO 2020 and Publications in The Lancet Oncology Phase III SANET-p demonstrated surufatinib reduces the risk of disease progression or death by 51% in patients with pancreatic neuroendocrine tumors ("N
Read more →HCMChi-Med Announces Second NDA Acceptance in China for Surufatinib in Pancreatic Neuroendocrine Tumors Hong Kong, Shanghai, & Florham Park, NJ: Thursday
Chi-Med Announces Second NDA Acceptance in China for Surufatinib in Pancreatic Neuroendocrine Tumors Hong Kong, Shanghai, & Florham Park, NJ: Thursday, September 17, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announces that its New Drug Applicatio
Read more →HCMChi-Med Initiates FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer Hong Kong, Shanghai, & Florham Park, NJ: Friday
Chi-Med Initiates FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer Hong Kong, Shanghai, & Florham Park, NJ: Friday, September 4, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) has initiated FRESCO-2, a Phase III registratio
Read more →HCMChi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Intrahepatic Cholangiocarcinoma in China Hong Kong, Shanghai, & Florham Park, NJ: Thursday
Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Intrahepatic Cholangiocarcinoma in China Hong Kong, Shanghai, & Florham Park, NJ: Thursday, September 3, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) has initiated a Phase II study o
Read more →HCMChi-Med Highlights Clinical Data to be Presented at the Upcoming ESMO Virtual Congress 2020 Hong Kong, Shanghai, & Florham Park, NJ: Monday
Chi-Med Highlights Clinical Data to be Presented at the Upcoming ESMO Virtual Congress 2020 Hong Kong, Shanghai, & Florham Park, NJ: Monday, August 24, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announces that new and updated analyses on the studi
Read more →HCMGrant of Share Options under Share Option Scheme Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, August 12, 20 20 : Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) announces that on
Grant of Share Options under Share Option Scheme Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, August 12, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) announces that on August 11, 2020, it granted share options under the Share Option Scheme conditio
Read more →HCMChi-Med Plans to Submit Marketing Authorization Application for Surufatinib Following Scientific Advice from EMA's CHMP Hong Kong, Shanghai, & Florham Park, NJ: Monday
Chi-Med Plans to Submit Marketing Authorization Application for Surufatinib Following Scientific Advice from EMA's CHMP Hong Kong, Shanghai, & Florham Park, NJ: Monday, August 10, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announces that it receiv
Read more →HCMx200B; Chi-Med Reports 2020 Interim Results and Provides Updates on Key Clinical Programs – Strong global pipeline progress – three U.S. FDA 1 Fast Track Designations; surufatinib U.S. NDA 2 preparations un
Chi-Med Reports 2020 Interim Results and Provides Updates on Key Clinical Programs Strong global pipeline progress three U.S. FDA1 Fast Track Designations; surufatinib U.S. NDA2 preparations underway; and initiation of global Phase III for fruquintinib Two further NDAs submitte
Read more →HCMBlock Admission Application London: Thursday
Block Admission Application London: Thursday, July 30, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announces an application has been made to the London Stock Exchange plc for a block admission of 30,221,458 ordinary shares, par value of US$0.10 eac
Read more →HCMChi-Med's NDA for Savolitinib in Non-Small Cell Lung Cancer Granted Priority Review in China Hong Kong, Shanghai & Florham Park, NJ: Tuesday
Chi-Med's NDA for Savolitinib in Non-Small Cell Lung Cancer Granted Priority Review in China Hong Kong, Shanghai & Florham Park, NJ: Tuesday, July 28, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announced that the China National Medical Products Ad
Read more →HCMChi-Med Initiates a Phase I Trial of IDH1/2 Dual Inhibitor in Patients with Hematological Malignancies in China - HMPL-306 is the ninth innovative oncology drug candidate discovered in house by Chi-Med - Ho
Chi-Med Initiates a Phase I Trial of IDH1/2 Dual Inhibitor in Patients with Hematological Malignancies in China - HMPL-306 is the ninth innovative oncology drug candidate discovered in house by Chi-Med - Hong Kong, Shanghai & Florham Park, NJ: Friday, July 24, 2020: Hutchison C
Read more →HCMNotification of Dilution of Voting Rights London: Tuesday
Notification of Dilution of Voting Rights London: Tuesday, July 7, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) was notified that CK Hutchison Holdings Limited ("CK Hutchison") shareholding1 in Chi-Med remains unchanged, at 332,478,770 ordinary shares of
Read more →HCMBlocklisting Six Monthly Return London: Monday
Blocklisting Six Monthly Return London: Monday, June 29, 2020: Hutchison China MediTech Limited ("Chi-Med" or the "Company") (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: (a
Read more →HCMChi-Med to Announce 2020 Half-Year Financial Results London: Friday
Chi-Med to Announce 2020 Half-Year Financial Results London: Friday, June 26, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) will be announcing its interim results for the six months ended June 30, 2020 on Thursday, July 30, 2020 at 12:00 noon British Summe
Read more →HCMChi-Med Announces Fruquintinib Granted U.S. FDA Fast Track Designation for Metastatic Colorectal Cancer London: Thursday
Chi-Med Announces Fruquintinib Granted U.S. FDA Fast Track Designation for Metastatic Colorectal Cancer London: Thursday, June 18, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration ("FDA") has granted
Read more →HCMChi-Med Announces US$95 million Guangzhou Land Compensation Agreement London: Tuesday
Chi-Med Announces US$95 million Guangzhou Land Compensation Agreement London: Tuesday, June 9, 2020: Hutchison China MediTech Limited ( Chi-Med ) (Nasdaq/AIM: HCM) today announces that Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ( HBYS ), its 50:50 jo
Read more →HCMChi-Med Announces the Continuation of Phase III FRUTIGA Study of Fruquintinib in Second-Line Gastric Cancer in China Following a Planned Interim Data Review London: Thursday
Chi-Med Announces the Continuation of Phase III FRUTIGA Study of Fruquintinib in Second-Line Gastric Cancer in China Following a Planned Interim Data Review London: Thursday, June 4, 2020: Hutchison China MediTech Limited ( Chi-Med ) (Nasdaq/AIM: HCM) today announces that the In
Read more →HCMChi-Med Plans to Submit NDA for Surufatinib Following Pre-NDA Meeting with the U.S. FDA London: Monday
Chi-Med Plans to Submit NDA for Surufatinib Following Pre-NDA Meeting with the U.S. FDA London: Monday June 1, 2020: Hutchison China MediTech Limited ( Chi-Med ) (Nasdaq/AIM: HCM) today announces that it has held its pre-New Drug Application ( NDA ) meeting with the U.S. Food an
Read more →HCMChi-Med Announces NDA Acceptance in China for Savolitinib in the Treatment of Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations — First NDA filing of savolitinib globally — ȁ
Chi-Med Announces NDA Acceptance in China for Savolitinib in the Treatment of Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations First NDA filing of savolitinib globally Chi-Med seeking first-in-class Chinese marketing authorization for a selective MET inhibitor Lo
Read more →HCMChi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab – Collaboration to explore multiple solid tumor cancer indications &#x
Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab Collaboration to explore multiple solid tumor cancer indications Initial development focused on multi-cohort trials in the U.S., Europe, China and Au
Read more →HCMChi-Med Highlights Clinical Data to be Presented at the Upcoming ASCO20 Virtual Scientific Program London: Thursday
Chi-Med Highlights Clinical Data to be Presented at the Upcoming ASCO20 Virtual Scientific Program London: Thursday, May 14, 2020: Hutchison China MediTech Limited ( Chi-Med ) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the ongoing studies of savolitinib,
Read more →HCMChi-Med to Attend Upcoming Investor Conferences London: Monday
Chi-Med to Attend Upcoming Investor Conferences London: Monday, May 11, 2020: Hutchison China MediTech Limited ( Chi-Med ) (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of Chi-Med, will participate in a virtual fireside chat at the Bank of Ame
Read more →HCMGrant of Share Options under Share Option Scheme London: Wednesday
Grant of Share Options under Share Option Scheme London: Wednesday, April 29, 2020: Hutchison China MediTech Limited ( Chi-Med ) (Nasdaq/AIM: HCM) announces that on April 28, 2020, in accordance with its new incentive policy outlined in its full year results announcement on Marc
Read more →HCMResults of Annual General Meeting London: Monday
Results of Annual General Meeting London: Monday, April 27, 2020: Hutchison China MediTech Limited ( Chi-Med ) (Nasdaq/AIM: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting ( AGM ) held on April 27, 2020 were duly passe
Read more →HCMChi-Med Highlights Presentations of Surufatinib at the Upcoming AACR Virtual Annual Meetings London: Wednesday
Chi-Med Highlights Presentations of Surufatinib at the Upcoming AACR Virtual Annual Meetings London: Wednesday, April 22, 2020: Hutchison China MediTech Limited ( Chi-Med ) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the ongoing studies of surufatinib will
Read more →HCMGrant of Awards under Long Term Incentive Plan and Share Options under Share Option Scheme London: Tuesday
Grant of Awards under Long Term Incentive Plan and Share Options under Share Option Scheme London: Tuesday, April 21, 2020: Hutchison China MediTech Limited ( Chi-Med ) (Nasdaq/AIM: HCM) announces that on April 20, 2020, in accordance with the new incentive policy outlined in it
Read more →HCMChi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors London: Friday
Chi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors London: Friday, April 17, 2020: Hutchison China MediTech Limited ( Chi-Med ) (Nasdaq/AIM: HCM) today announces that the U.S. Food
Read more →HCMChi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Malignant Mesothelioma in China London: Tuesday
Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Malignant Mesothelioma in China London: Tuesday, March 31, 2020: Hutchison China MediTech Limited ( Chi-Med ) (Nasdaq/AIM: HCM) has initiated a Phase II study of HMPL-453, its novel small molecule inhibitor
Read more →HCMAnnual Report and Notice of Annual General Meeting London: Wednesday
2019 Annual Report and Notice of Annual General Meeting London: Wednesday, March 25, 2020: Hutchison China MediTech Limited ( Chi-Med ) (Nasdaq/ AIM: HCM) today announces that its 2019 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy ( AGM
Read more →HCMVesting of awards under the Long Term Incentive Plan London: Monday
Vesting of awards under the Long Term Incentive Plan London: Monday, March 9, 2020: Hutchison China MediTech Limited ( Chi-Med ) (Nasdaq/AIM: HCM) announces that following the announcement of the 2019 annual results of Chi-Med on March 3, 2020, the following awards granted under
Read more →HCMChi-Med Reports 2019 Full Year Results and Provides Updates on Key Clinical Programs Company to Host Annual Results Conference Call Today at 1:00 p.m. GMT / 8:00 a.m. EST / 9:00 p.m. HKT London: Tuesday
Chi-Med Reports 2019 Full Year Results and Provides Updates on Key Clinical Programs Company to Host Annual Results Conference Call Today at 1:00 p.m. GMT / 8:00 a.m. EST / 9:00 p.m. HKT London: Tuesday, March 3, 2020: Hutchison China MediTech Limited ( Chi-Med ) (Nasdaq/AIM: H
Read more →HCMChi-Med to announce 2019 Final Results on Tuesday
Chi-Med to announce 2019 Final Results on Tuesday, March 3, 2020 adjustment to announcement and presentation logistics due to travel restrictions London: Tuesday, February 25, 2020: Further to its announcement dated January 31, 2020, Hutchison China MediTech Limited ( Chi-Med )
Read more →HCMChi-Med Highlights Updated Phase II Savolitinib / Imfinzi ® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2020 ASCO Genitourinary Cancers Symposium London: Monday
Chi-Med Highlights Updated Phase II Savolitinib / Imfinzi Combination Data in Advanced Papillary Renal Cell Carcinoma at 2020 ASCO Genitourinary Cancers Symposium London: Monday, February 10, 2020: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announced th
Read more →HCMNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Chi-Med Announces the Exercise
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Chi-Med Announces the Exercise of Underwriters Over-allotment Option for Public Offering
Read more →HCMChi-Med to Announce 2019 Final Results London: Friday
Chi-Med to Announce 2019 Final Results London: Friday, January 31, 2020: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) will announce its final results for the year ended December 31, 2019 on Tuesday, March 3, 2020 at 7:00 am Greenwich Mean Time (GMT). A present
Read more →HCMTR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) I 1a. Identity of the issuer or the underlying
TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) I 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attac
Read more →HCMNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Chi-Med Announces Pricing of US
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Chi-Med Announces Pricing of US$110 Million Public Offering of ADSs London: Thursday, Jan
Read more →HCMNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Chi-Med Announces Proposed Publ
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Chi-Med Announces Proposed Public Offering of ADSs London: Tuesday, January 21, 2020: Hut
Read more →HCMHutchison China MediTech Limited Condensed Consolidated Balance Sheets (in US$'000, except share data) Note
-- Click here to rapidly navigate through this document Hutchison China MediTech Limited Condensed Consolidated Balance Sheets (in US$'000, except share data) Note September 30, 2019 December 31, 2018 (Unaudited) Assets Current assets Cash and cash e
Read more →HCMChi-Med Announces that Surufatinib Phase III SANET-p Study Has Already Achieved its Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China and Will Stop Early London: Monday
Chi-Med Announces that Surufatinib Phase III SANET-p Study Has Already Achieved its Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China and Will Stop Early London: Monday, January 20, 2020: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today a
Read more →HCMChi-Med Initiates a Phase II Trial of Surufatinib in Combination with Tuoyi in Patients with Advanced Solid Tumors London: Monday
Chi-Med Initiates a Phase II Trial of Surufatinib in Combination with Tuoyi in Patients with Advanced Solid Tumors London: Monday, January 13, 2020: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) has initiated a Phase II study in China of surufatinib in combinati
Read more →HCMChi-Med to Present at the 38 th Annual JP Morgan Healthcare Conference London: Monday
Chi-Med to Present at the 38th Annual JP Morgan Healthcare Conference London: Monday, January 6, 2020: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 38th Annual JP Morgan Healthcar
Read more →HCMBlocklisting Six Monthly Return London: Tuesday
Blocklisting Six Monthly Return London: Tuesday, December 31, 2019: Hutchison China MediTech Limited ( Chi-Med or the Company ) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme:
Read more →HCMChi-Med's New Drug Application for Surufatinib in Non-Pancreatic Neuroendocrine Tumors Granted Priority Review in China London: Friday
Chi-Med's New Drug Application for Surufatinib in Non-Pancreatic Neuroendocrine Tumors Granted Priority Review in China London: Friday, December 20, 2019: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that the Center for Drug Evaluation (CDE) of
Read more →HCMGrant of Share Options under Share Option Scheme London: Thursday
Grant of Share Options under Share Option Scheme London: Thursday, December 12, 2019: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) announces that on December 11, 2019, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at it
Read more →HCMChi-Med's Elunate ® (Fruquintinib Capsules) Included in the National Reimbursement Drug List in China London: Thursday
Chi-Med's Elunate (Fruquintinib Capsules) Included in the National Reimbursement Drug List in China London: Thursday, November 28, 2019: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that Elunate (fruquintinib capsules), its national class 1 targ
Read more →HCMChi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancreatic Neuroendocrine Tumors London: Monday
Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancreatic Neuroendocrine Tumors London: Monday, November 25, 2019: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that the U.S. Food and Drug Administration ( FDA ) has granted
Read more →HCMChi-Med Announces NDA Acceptance in China for Surufatinib in Non-Pancreatic Neuroendocrine Tumors London: Monday
Chi-Med Announces NDA Acceptance in China for Surufatinib in Non-Pancreatic Neuroendocrine Tumors London: Monday, November 11, 2019: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that its New Drug Application ( NDA ) for surufatinib for the treat
Read more →HCMChi-Med highlights publication of Phase II data showing promising efficacy for Savolitinib in MET-amplified gastric cancers London: Thursday
Chi-Med highlights publication of Phase II data showing promising efficacy for Savolitinib in MET-amplified gastric cancers London: Thursday, October 17, 2019: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today highlighted the publication of results from the Ph
Read more →HCMInnovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors SUZHOU, CHINA and LONDON
Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors SUZHOU, CHINA and LONDON, UK, Thursday, October 10, 2019 Innovent Biologics, Inc. ( Innovent ) (HKEX: 01801) and Hutchison China MediTech Limited ( Chi-Med
Read more →HCMChi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients with Advanced Relapsed or Refractory Lymphoma London: Friday
Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients with Advanced Relapsed or Refractory Lymphoma London: Friday, October 4, 2019: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-523,
Read more →HCMNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION CK Hutchison prices offering of
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confir
Read more →HCMChi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Safety Data Presented at the 2019 ESMO Annual Meeting Surufatinib achieved primary endpoint, reducing the risk of progression or dea
Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Safety Data Presented at the 2019 ESMO Annual Meeting Surufatinib achieved primary endpoint, reducing the risk of progression or death by 67% in patients with non-pancreatic neuroendocrine tumors ( NET ) i
Read more →HCMChi-Med Highlights Presentation of Clinical Data from the Successful SANET - ep Phase III Trial at ESMO Annual Meeting – Late-Breaking Abstract of the positive SANET-ep Phase III trial of surufatinib
Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-ep Phase III Trial at ESMO Annual Meeting Late-Breaking Abstract of the positive SANET-ep Phase III trial of surufatinib in patients with non-pancreatic neuroendocrine tumors ( NET ) to be presented Conf
Read more →HCMChi-Med Highlights Oral Presentations at 2019 CSCO Annual Meeting London: Wednesday
Chi-Med Highlights Oral Presentations at 2019 CSCO Annual Meeting London: Wednesday, September 18, 2019: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) shares additional analyses from three completed and ongoing clinical studies of fruquintinib and savolitinib at
Read more →HCMChi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma London: Tuesday
Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma London: Tuesday, September 3, 2019: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-68
Read more →HCMChi-Med Initiates a Phase I Trial of HMPL-523 in Patients with Immune Thrombocytopenia (ITP) in China London: Friday
Chi-Med Initiates a Phase I Trial of HMPL-523 in Patients with Immune Thrombocytopenia (ITP) in China London: Friday, August 23, 2019: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase ( Sy
Read more →HCMChi-Med Reports 2019 Interim Results and Provides Updates on Key Clinical Programs FINANCIAL REVIEW OPERATIONS REVIEW INTERIM UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Hutchison China MediTech Limited Condens
-- Click here to rapidly navigate through this document Chi-Med Reports 2019 Interim Results and Provides Updates on Key Clinical Programs London: Tuesday, July 30, 2019: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces its unaudited financial res
Read more →HCMChi-Med to Announce 2019 Half-Year Financial Results London: Wednesday
Chi-Med to Announce 2019 Half-Year Financial Results London: Wednesday, July 3, 2019: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2019 on Tuesday, July 30, 2019 at 7:00 am British Summer
Read more →HCMBlocklisting Six Monthly Return London: Friday
Blocklisting Six Monthly Return London: Friday, June 28, 2019: Hutchison China MediTech Limited ( Chi-Med or the Company ) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: (a)
Read more →HCMNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Chi-Med Announces Pricing of Up
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Chi-Med Announces Pricing of Upsized U.S. Public Secondary Offering of American Depositar
Read more →HCMChi-Med Announces that Surufatinib Phase III SANET-ep Study Has Met its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early London: Friday
Chi-Med Announces that Surufatinib Phase III SANET-ep Study Has Met its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early London: Friday, June 14, 2019: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM
Read more →HCMBlock Admission Applications and Total Voting Rights London: Wednesday
Block Admission Applications and Total Voting Rights London: Wednesday, June 12, 2019: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that the following applications have been made to the London Stock Exchange plc for the block admission of ordina
Read more →HCMResults of Extraordinary General Meeting London: Wednesday
Results of Extraordinary General Meeting London: Wednesday, May 29, 2019: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that the ordinary resolution and special resolution put to its Extraordinary General Meeting ( EGM ) held on May 29, 2019 were
Read more →HCMNotice of Extraordinary General Meeting and Shareholders' Circular London: Friday
Notice of Extraordinary General Meeting and Shareholders' Circular London: Friday, May 3, 2019: Hutchison China MediTech Limited ( Chi-Med or Company ) (AIM/Nasdaq: HCM) today announces that an Extraordinary General Meeting ( EGM ) is to be held at 11:00 a.m. London time on Wedn
Read more →HCMResults of Annual General Meeting London: Wednesday
Results of Annual General Meeting London: Wednesday, April 24, 2019: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting ( AGM ) held on April 24, 2019 were duly pa
Read more →HCMBUSINESS OVERVIEW We are an innovative, commercial-stage biopharmaceutical company based in China aiming to become a global leader in the discovery, development and commercialization of targeted therapies and immunothera
BUSINESS OVERVIEW We are an innovative, commercial-stage biopharmaceutical company based in China aiming to become a global leader in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Read more →HCMChi-Med Initiates a Phase IIb/III Trial of Surufatinib in Patients with Unresectable or Metastatic Biliary Tract Cancer in China London: Friday
Chi-Med Initiates a Phase IIb/III Trial of Surufatinib in Patients with Unresectable or Metastatic Biliary Tract Cancer in China London: Friday, March 29, 2019: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) has initiated a registration-enabling Phase IIb/III stu
Read more →HCMChi-Med Highlights Oral Presentations on Savolitinib Lung Cancer Programs at AACR Annual Meeting London: Thursday
Chi-Med Highlights Oral Presentations on Savolitinib Lung Cancer Programs at AACR Annual Meeting London: Thursday, March 28, 2019: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) will share further data on the savolitinib development programs in lung cancer at the
Read more →HCMAnnual Report and Notice of Annual General Meeting London: Thursday
2018 Annual Report and Notice of Annual General Meeting London: Thursday, March 21, 2019: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that its 2018 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have bee
Read more →HCMChi-Med Reports 2018 Full Year Results and Provides Updates on Key Clinical Programs London: Monday
Chi-Med Reports 2018 Full Year Results and Provides Updates on Key Clinical Programs London: Monday, March 11, 2019: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces its audited financial results for the year ended December 31, 2018 and provides up
Read more →HCMChi-Med Highlights Preliminary Phase II Savolitinib / Imfinzi ® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2019 ASCO Genitourinary Cancers Symposium London: Tuesday
Chi-Med Highlights Preliminary Phase II Savolitinib / Imfinzi Combination Data in Advanced Papillary Renal Cell Carcinoma at 2019 ASCO Genitourinary Cancers Symposium London: Tuesday, February 12, 2019: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announc
Read more →HCMChi-Med to Announce 2018 Final Results London: Friday
Chi-Med to Announce 2018 Final Results London: Friday, February 8, 2019: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) will announce its final results for the year ended December 31, 2018 on Monday, March 11, 2019 at 7:00 am Greenwich Mean Time (GMT). An analys
Read more →HCMChi-Med to Present at the 37 th Annual JP Morgan Healthcare Conference London: Monday
Chi-Med to Present at the 37th Annual JP Morgan Healthcare Conference London: Monday, January 7, 2019: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 37th Annual JP Morgan Healthcar
Read more →HCMChi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company – Chi-Med acquires right to determine & conduct all future life cycle indication development of
Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company Chi-Med acquires right to determine & conduct all future life cycle indication development of fruquintinib monotherapy as well as innovative combinations in China
Read more →HCMChi-Med Enters into Multiple Collaborations to Evaluate Combinations of Surufatinib and Fruquintinib with PD-1 Checkpoint Inhibitors London: Thursday
Chi-Med Enters into Multiple Collaborations to Evaluate Combinations of Surufatinib and Fruquintinib with PD-1 Checkpoint Inhibitors London: Thursday, November 29, 2018: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) entered into four collaboration agreements to
Read more →HCMChi-Med Announces First Commercial Launch of Fruquintinib Capsules (Elunate ® ) London: Monday
Chi-Med Announces First Commercial Launch of Fruquintinib Capsules (Elunate ) London: Monday, November 26, 2018: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces the first commercial launch of fruquintinib capsules (Elunate ) with the initiation of
Read more →HCMChi-Med Announces Phase III FALUCA Trial Results for Fruquintinib in Third-Line, Advanced Non-Small Cell Lung Cancer in China – Trial did not meet the primary endpoint of overall survival despite improvement in pr
Chi-Med Announces Phase III FALUCA Trial Results for Fruquintinib in Third-Line, Advanced Non-Small Cell Lung Cancer in China Trial did not meet the primary endpoint of overall survival despite improvement in progression-free survival London: Friday, November 16, 2018: Hutchiso
Read more →HCMGrant of Share Options under Share Option Scheme London: Monday
Grant of Share Options under Share Option Scheme London: Monday, October 22, 2018: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) announces that on October 19, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its An
Read more →HCMChi-Med Initiates a Phase I Trial of HMPL-523 in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia in China London: Thursday
Chi-Med Initiates a Phase I Trial of HMPL-523 in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia in China London: Thursday, October 18, 2018: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) has initiated a Phase I study of HMPL-523, i
Read more →HCMAppointment of HSBC Bank plc as Joint Corporate Broker in London London: Friday
Appointment of HSBC Bank plc as Joint Corporate Broker in London London: Friday, October 5, 2018: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that it has appointed HSBC Bank plc as its joint Corporate Broker in London with immediate effect. Pan
Read more →HCMChi-Med Announces the Approval of Fruquintinib Capsules for Previously Treated Colorectal Cancer in China – Fruquintinib capsules provide a new oral treatment option for patients with metastatic colorectal cancer
Chi-Med Announces the Approval of Fruquintinib Capsules for Previously Treated Colorectal Cancer in China Fruquintinib capsules provide a new oral treatment option for patients with metastatic colorectal cancer and will be marketed as Elunate Elunate data published in JAMA demo
Read more →HCMGrant of Share Options under Share Option Scheme London: Tuesday
Grant of Share Options under Share Option Scheme London: Tuesday, August 7, 2018: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) announces that on August 6, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annua
Read more →HCMChi-Med Reports 2018 Interim Results and Updates Shareholders on Key Clinical Programs FINANCIAL REVIEW OPERATIONS REVIEW UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Hutchison China MediTech Limited Condensed C
-- Click here to rapidly navigate through this document Chi-Med Reports 2018 Interim Results and Updates Shareholders on Key Clinical Programs London: Friday, July 27, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces its unaudited financial
Read more →HCMChi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Sulfatinib in Pancreatic Neuroendocrine Tumors and Biliary Tract Cancer in the United States London: Monday
Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Sulfatinib in Pancreatic Neuroendocrine Tumors and Biliary Tract Cancer in the United States London: Monday, July 23, 2018: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) has initiated a Phase Ib/II proof-
Read more →HCMChi-Med to Announce 2018 Half-Year Financial Results London: Friday
Chi-Med to Announce 2018 Half-Year Financial Results London: Friday, June 29, 2018: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2018 on Friday, July 27, 2018 at 7:00 am British Summer Tim
Read more →HCMChi-Med Presents Further Fruquintinib FRESCO Trial Data at ASCO 2018 Annual Meeting – Chi-Med makes additional FRESCO presentations at ASCO 2018, following oral presentation at ASCO 2017 showing that
Chi-Med Presents Further Fruquintinib FRESCO Trial Data at ASCO 2018 Annual Meeting Chi-Med makes additional FRESCO presentations at ASCO 2018, following oral presentation at ASCO 2017 showing that study met all endpoints with a manageable safety profile and lower off-target tox
Read more →HCMTotal Voting Rights London: Thursday
London: Thursday, May 31, 2018: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) hereby notifies the market that as at May 31, 2018, the issued share capital of Chi-Med consisted of 66,515,756 ordinary shares of US$1.00 each, with each share carrying one right to vo
Read more →HCMChi-Med to Present at Bank of America Merrill Lynch Annual Health Care Conference London: Friday
Chi-Med to Present at Bank of America Merrill Lynch Annual Health Care Conference London: Friday, May 11, 2018: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) announced today that Christian Hogg, Chief Executive Officer, will present at the Bank of America Merril
Read more →HCMResults of Annual General Meeting London: Friday
Results of Annual General Meeting London: Friday, April 27, 2018: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting ( AGM ) held on April 27, 2018 were duly passe
Read more →HCMVesting of awards under the Long Term Incentive Plan London: Wednesday
Vesting of awards under the Long Term Incentive Plan London: Wednesday, March 28, 2018: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) announces that following the publication of the 2017 annual report of Chi-Med on March 26, 2018, the following awards granted un
Read more →HCMAnnual Report and Notice of Annual General Meeting London: Monday
2017 Annual Report and Notice of Annual General Meeting London: Monday, March 26, 2018: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that its 2017 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been
Read more →HCMDirector's Share Dealing London: Wednesday
Director's Share Dealing London: Wednesday, March 21, 2018: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) has received notification that the spouse of Mr Graeme Jack, Independent Non-executive Director, purchased a total of 3,000 American Depositary Shares of th
Read more →HCMDirector's Share Dealing London: Monday
Director's Share Dealing London: Monday, March 19, 2018: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) has received notification that Dr Dan Eldar, Non-executive Director, purchased a total of 2,768 American Depositary Shares of the Company ( ADSs , each represe
Read more →HCMHutchison China MediTech Limited ( Chi-Med ) Reports Final Results for the Year Ended
Hutchison China MediTech Limited ( Chi-Med ) Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs Group: Year of major progress; results in line with guidance Group revenue up 12% to $241.2 million (2016: $216.1m); Net lo
Read more →HCMChi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Epitinib in Glioblastoma in China London: Tuesday
Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Epitinib in Glioblastoma in China London: Tuesday, March 6, 2018: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) has initiated a Phase Ib/II proof-of-concept study of epitinib in glioblastoma patients with
Read more →HCMChi-Med Completes Enrollment of 527 Patients in Pivotal Phase III FALUCA Trial with Fruquintinib in Lung Cancer London: Tuesday
Chi-Med Completes Enrollment of 527 Patients in Pivotal Phase III FALUCA Trial with Fruquintinib in Lung Cancer London: Tuesday, February 13, 2018: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) has completed patient enrollment of FALUCA, its Phase III pivotal tr
Read more →HCMChi-Med to Announce 2017 Final Results London: Monday
Chi-Med to Announce 2017 Final Results London: Monday, February 5, 2018: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) will be announcing its final results for the year ended December 31, 2017 on Monday, March 12, 2018 at 7:00 am Greenwich Mean Time (GMT). An a
Read more →HCMChi-Med Initiates Fruquintinib U.S. Clinical Trials London: Friday
Chi-Med Initiates Fruquintinib U.S. Clinical Trials London: Friday, December 15, 2017: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) has initiated the United States Phase I bridging clinical trial of fruquintinib. Fruquintinib is a highly selective and potent or
Read more →HCMTR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights ar
TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Hutchison China MediTech Limited; Legal Ent
Read more →HCMChi-Med Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately US$301.3 Million on the Nasdaq Global Select Market London: Monday
Chi-Med Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately US$301.3 Million on the Nasdaq Global Select Market London: Monday, October 30, 2017: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) announced today t
Read more →HCMNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Chi-Med Announces the Full Exer
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Chi-Med Announces the Full Exercise of Underwriters' Over-allotment Option London: Friday
Read more →HCMChi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market London: Wednesday
Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market London: Wednesday, October 25, 2017: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) announced today the pricing of the underwritten public offering pre
Read more →HCMChi-Med Announces Proposed Offering of ADSs London: Tuesday
Chi-Med Announces Proposed Offering of ADSs London: Tuesday, October 24, 2017: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) announced today that it intends to offer, subject to market and other conditions, US$262.0 million of American Depositary Shares ("ADSs")
Read more →HCMTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Hutchison China MediTech Limited 2 Reason for the notificatio
Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi Proxy Voting: 10. Name of the proxy holder: 11. Number of voting rights proxy holder will cease to hold: 12. Date on which proxy holder will
Read more →HCMChi-Med and AstraZeneca's Savolitinib Shows Encouraging Clinical Activity in Second-Line EGFR Mutation-Positive Lung Cancer with MET- Amplification – Data for savolitinib in combination with Tagrisso ® or Ire
Chi-Med and AstraZeneca's Savolitinib Shows Encouraging Clinical Activity in Second-Line EGFR Mutation-Positive Lung Cancer with MET-Amplification Data for savolitinib in combination with Tagrisso or Iressa presented at World Conference on Lung Cancer New data give insights int
Read more →HCMChi-Med Reports Preliminary Phase II data on Fruquintinib Combination in First-Line Lung Cancer – Fruquintinib in combination with Iressa ® (gefitinib) shows promising efficacy and an acceptable
Chi-Med Reports Preliminary Phase II data on Fruquintinib Combination in First-Line Lung Cancer Fruquintinib in combination with Iressa (gefitinib) shows promising efficacy and an acceptable safety profile Further validation of strong potential for use of fruquintinib in combi
Read more →HCMAppointment of Director London: Thursday
Appointment of Director London: Thursday, October 12, 2017: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that Professor Mok, Shu Kam Tony has been appointed as Independent Non-Executive Director and member of the Technical Committee with effect
Read more →HCMDirector's Share Dealing London: Thursday
Director's Share Dealing London: Thursday, August 31, 2017: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) has received notifications that Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated with Mr To, purchas
Read more →HCMChi Med Initiates a Phase I Clinical Trial of Selective PI3Kδ Inhibitor HMPL 689 in Lymphoma Patients in China London: Tuesday
Chi Med Initiates a Phase I Clinical Trial of Selective PI3K Inhibitor HMPL 689 in Lymphoma Patients in China London: Tuesday, August 29, 2017: Hutchison China MediTech Limited ( Chi Med ) (AIM/Nasdaq: HCM) has initiated a Phase I clinical trial of HMPL 689 in China. HMPL-689 is
Read more →HCMDirector's Share Dealing London: Tuesday
Director's Share Dealing London: Tuesday, August 22, 2017: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) has received notifications that Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 4,000 American Depositary Shares of the Com
Read more →HCMDirectors' Share Dealing London: Friday
Directors' Share Dealing London: Friday, August 18, 2017: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) has received notifications that:- Following the above purchases, (i) Mr To is interested in 118,489 ADSs (in Dynamic Drive Trust ( DDT ) and WT of which his
Read more →HCMDirectors' Share Dealing London: Tuesday
Directors' Share Dealing London: Tuesday, August 15, 2017: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) has received notifications that:- Following the above purchases, (i) Mr To is interested in 113,589 ADSs (in DDT and Wencheng Trust of which his family memb
Read more →HCMDirectors' Share Dealing London: Monday
Directors' Share Dealing London: Monday, August 7, 2017: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) has received notifications that:- Following the above purchases, (i) Mr To is interested in 110,401 ADSs (in DDT and WT of which his family members are the be
Read more →HCMChi-Med Reports 2017 Interim Results and Updates Shareholders on Key Clinical Programs London: Monday
Chi-Med Reports 2017 Interim Results and Updates Shareholders on Key Clinical Programs London: Monday, July 31, 2017: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM), the China-based biopharmaceutical company focused on discovering and developing targeted therapie
Read more →HCMAstraZeneca PLC (“AstraZeneca”) (LON/STO/NYSE: AZN) Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) Chi-Med and AstraZeneca Initiate SAVOIR, a Global Phase III Trial of Savoliti
Chi-Med and AstraZeneca Initiate SAVOIR, a Global Phase III Trial of Savolitinib in Papillary Renal Cell Carcinoma London: Thursday, June 29, 2017: Chi-Med and AstraZeneca today announce that they have initiated a global pivotal Phase III, open-label, randomized multi-center re
Read more →HCMChi Med Initiates a Phase I/II Clinical Trial of Novel FGFR Inhibitor HMPL 453 in China London: Thursday
Chi Med Initiates a Phase I/II Clinical Trial of Novel FGFR Inhibitor HMPL 453 in China London: Thursday, June 22, 2017: Hutchison China MediTech Limited ( Chi Med ) (AIM/Nasdaq: HCM) has just initiated a Phase I/II clinical trial of HMPL 453 in China. HMPL 453 is a novel, highl
Read more →HCMChi-Med Submits New Drug Application to CFDA for Fruquintinib in Advanced Colorectal Cancer – Application accepted by CFDA for technical review by the Center for Drug Evaluation – – Triggers RMB30.8
Chi-Med Submits New Drug Application to CFDA for Fruquintinib in Advanced Colorectal Cancer Application accepted by CFDA for technical review by the Center for Drug Evaluation Triggers RMB30.8 million milestone payment from Eli Lilly and Company ( Lilly ) London: Monday, June
Read more →HCMChi-Med Highlights Phase III Fruquintinib Data in Oral Presentation at ASCO Chicago: Monday
Chi-Med Highlights Phase III Fruquintinib Data in Oral Presentation at ASCO Chicago: Monday, June 5, 2017: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) announced that results from its pivotal Phase III trial with fruquintinib, its novel vascular endothelial gro
Read more →HCMChi-Med Presents Clinical Data at ASCO 2017 Annual Meeting – FRESCO Phase III trial results for fruquintinib in colorectal cancer in an oral presentation – – Five abstracts in total acc
Chi-Med Presents Clinical Data at ASCO 2017 Annual Meeting FRESCO Phase III trial results for fruquintinib in colorectal cancer in an oral presentation Five abstracts in total accepted for fruquintinib, savolitinib and sulfatinib London: Thursday, May 18, 2017: Hutchison China
Read more →HCMResults of Annual General Meeting London: Thursday
Results of Annual General Meeting London: Thursday, April 27, 2017: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting ( AGM ) held on April 27, 2017 were duly pas
Read more →HCMChi-Med Presented Pre-clinical Data for Fruquintinib and Sulfatinib at the American Association for Cancer Research Annual Meeting 2017 London: Friday
Chi-Med Presented Pre-clinical Data for Fruquintinib and Sulfatinib at the American Association for Cancer Research Annual Meeting 2017 London: Friday, April 7, 2017: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) presented pre-clinical data for fruquintinib and
Read more →HCMLondon: Friday, March 31, 2017: For information purposes, Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) hereby notifies the market that as at March 31, 2017, the i
London: Friday, March 31, 2017: For information purposes, Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) hereby notifies the market that as at March 31, 2017, the issued share capital of Chi-Med consisted of 60,715,323 ordinary shares of US$1.00 each, with each sh
Read more →HCMVesting of awards under the Long Term Incentive Plan
Vesting of awards under the Long Term Incentive Plan London: Wednesday, March 29, 2017: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) announces that following the publication of the 2016 annual report of Chi-Med on March 27, 2017, the following awards granted un
Read more →HCMLondon: Friday, March 24, 2017: Hutchison China MediTech Limited ( Chi-Med or the Company ) (AIM/Nasdaq: HCM) today announces that Dr Weiguo Su has been appointed as Executive Dire
Appointment of Director London: Friday, March 24, 2017: Hutchison China MediTech Limited ( Chi-Med or the Company ) (AIM/Nasdaq: HCM) today announces that Dr Weiguo Su has been appointed as Executive Director and member of Technical Committee with effect from March 27, 2017. Dr
Read more →HCMChi-Med to host R&D Briefings on March 29 & 30, 2017
Chi-Med to host R&D Briefings on March 29 & 30, 2017 London: Tuesday, March 21, 2017: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that it will host Research & Development ( R&D ) briefings in London and New York to provide an overview of the Co
Read more →HCMGrant of Awards under Long Term Incentive Plan
Grant of Awards under Long Term Incentive Plan London: Thursday, March 16, 2017: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) announces that on March 15, 2017, it granted conditional awards ( LTIP Awards ) under the Long Term Incentive Plan ( LTIP ) adopted by
Read more →HCMHutchison China MediTech Limited ( Chi-Med ) Reports Final Results for the Year Ended December 31 , 2016 and Updates Shareholders on Key Clinical Programs Group: Record revenue, net income and clinical investment in 2016
Hutchison China MediTech Limited ( Chi-Med ) Reports Final Results for the Year Ended December 31, 2016 and Updates Shareholders on Key Clinical Programs Group: Record revenue, net income and clinical investment in 2016 Group revenue up 21% to $216.1 million (2015: $178.2m); N
Read more →HCMChi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference of European Neuroendocrine Tumor Society
Chi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference of European Neuroendocrine Tumor Society London: Friday, March 10, 2017: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) presented data from the ongoing Phase Ib/I
Read more →HCMChi-Med Announces Positive Top-Line Results for FRESCO, its Phase III Pivotal Registration Trial of Fruquintinib in Patients with Locally Advanced or Metastatic Colorectal Cancer
Chi-Med Announces Positive Top-Line Results for FRESCO, its Phase III Pivotal Registration Trial of Fruquintinib in Patients with Locally Advanced or Metastatic Colorectal Cancer Trial met all primary and secondary endpoints Progressing to China NDA submission mid-2017 Full da
Read more →HCMLondon: Tuesday, February 28, 2017: Hutchison China MediTech Limited ( Chi-Med or the Company ) (AIM/Nasdaq: HCM) today announces that with effect from March 1, 2017:-
London: Tuesday, February 28, 2017: Hutchison China MediTech Limited ( Chi-Med or the Company ) (AIM/Nasdaq: HCM) today announces that with effect from March 1, 2017:- Mr Simon To, Chairman of Chi-Med said With the appointment of Mr Jack, the Company now completes the process of
Read more →HCMChi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma
Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma London: Monday, February 20, 2017: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that a Phase II study of savolitinib has been initiated in locally advanced or m
Read more →HCMChi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium London: Tuesday
Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium London: Tuesday, February 14, 2017: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) and AstraZeneca PLC ( AstraZeneca ) will present
Read more →HCMChi-Med to Announce 2016 Final Results London: Monday
Chi-Med to Announce 2016 Final Results London: Monday, February 6, 2017: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) will be announcing its final results for the year ended December 31, 2016 on Monday, March 13, 2017 at 7:00 am Greenwich Mean Time (GMT). An a
Read more →HCMChange of Directors London: Wednesday
London: Wednesday, February 1, 2017: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that with effect from today:- Dr Ferrante, aged 59, has more than 20 years of experience in the pharmaceutical industry. She was the former Chief Medical Officer a
Read more →HCMChange of Directors London: Monday
London: Monday, January 16, 2017: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces with effect from February 1, 2017, Mr Paul Rutherford Carter has been appointed as Senior Independent Non-Executive Director and member of the Audit Committee, Remuner
Read more →HCMChi-Med Initiates HMPL-523 Clinical Trials in Hematological Cancer in China London: Tuesday
Chi-Med Initiates HMPL-523 Clinical Trials in Hematological Cancer in China London: Tuesday, January 10, 2017: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that it has initiated a Phase I trial of its novel spleen tyrosine kinase ( Syk ) inhibit
Read more →HCMChi-Med Presents Pre-clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 American Society of Hematology Annual Meeting London: Tuesday
Chi-Med Presents Pre-clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 American Society of Hematology Annual Meeting London: Tuesday, December 6, 2016: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that data from a recent pre-clinica
Read more →HCMLondon: Wednesday, November 30, 2016: For information purposes, Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) hereby notifies the market that as at November 30, 20
London: Wednesday, November 30, 2016: For information purposes, Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) hereby notifies the market that as at November 30, 2016, the issued share capital of Chi-Med consisted of 60,703,323 ordinary shares of US$1.00 each, wit
Read more →HCMChi-Med to Present Data from Proof-of-Concept Clinical Trials for Fruquintinib and Epitinib at the 17th World Conference on Lung Cancer ( WCLC )
Chi-Med to Present Data from Proof-of-Concept Clinical Trials for Fruquintinib and Epitinib at the 17th World Conference on Lung Cancer ( WCLC ) London: Wednesday, November 23, 2016: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that results from
Read more →HCMChi-Med Presents Phase I Clinical Data for Selective Syk Inhibitor
Chi-Med Presents Phase I Clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 ACR/ARHP Annual Meeting London: Monday, November 14, 2016: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that data from a recent Phase I, first-in-human, dos
Read more →HCMLondon: Tuesday, November 1, 2016: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) has received notification that Mr Michael Howell, Independent Non-executive Direct
Director's Share Dealing London: Tuesday, November 1, 2016: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, sold 10,000 ordinary shares of US$1.00 each in Chi-Med (the Ordinary S
Read more →HCMChi-Med Commercial Platform Joint Venture Receives US$59.5 Million Land Compensation Payment · Shanghai agreement triggers a one-time gain to Chi-Med of US$38.2 million in Q4 2016 · Shanghai factory relocation
Chi-Med Commercial Platform Joint Venture Receives US$59.5 Million Land Compensation Payment London: Monday, October 31, 2016: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited ( SHPL ), its 50:50 Presc
Read more →HCMDirector s Share Dealing London: Wednesday, October 12 , 2016 : Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, has sol
Director s Share Dealing London: Wednesday, October 12, 2016: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, has sold 15,000 ordinary shares of US$1.00 each in Chi-Med (the Ordi
Read more →HCMDirector s Share Dealing London: Tuesday, August 9 , 2016 : Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) has received notification that the spouse of Mr Christopher Nash, Independent Non-executive Direc
Director s Share Dealing London: Tuesday, August 9, 2016: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) has received notification that the spouse of Mr Christopher Nash, Independent Non-executive Director, has purchased 3,120 and 42 ordinary shares of US$1.00 ea
Read more →HCMHutchison China MediTech Limited ( Chi-Med ) Reports Interim Results for the Six Months Ended
Hutchison China MediTech Limited ( Chi-Med ) Reports Interim Results for the Six Months Ended June 30, 2016, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs Group revenue up 27% to $104.5 million (H1 2015: $82.5m) and net income attributable to
Read more →HCMAstraZeneca PLC ( AstraZeneca ) Hutchison China MediTech Limited ( Chi-Med ) (LON/STO/NYSE: AZN) (AIM/Nasdaq: HCM) Chi-Med and AstraZeneca A mend C o-development A greement to A ccelerate S avolitinib Global Development
AstraZeneca PLC ( AstraZeneca ) Hutchison China MediTech Limited ( Chi-Med ) (LON/STO/NYSE: AZN) (AIM/Nasdaq: HCM) Chi-Med and AstraZeneca Amend Co-development Agreement to Accelerate Savolitinib Global Development Program First global pivotal Phase III in c-Met-driven papillar
Read more →HCMChi-Med to Announce 2016 Half-Year Financial Results London: Tuesday
Chi-Med to Announce 2016 Half-Year Financial Results London: Tuesday, July 5, 2016: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2016 on Tuesday, August 2, 2016 at 7:00 am British Summer T
Read more →HCMBlocklisting Six Monthly Return London: Wednesday
Blocklisting Six Monthly Return London: Wednesday, June 29, 2016: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: Hutchison China
Read more →HCMSavolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer Initiation of expanded Phase II trials in NSCLC triggers US$10 million milestone from AstraZeneca to Chi-Med New study builds on encou
Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer Initiation of expanded Phase II trials in NSCLC triggers US$10 million milestone from AstraZeneca to Chi-Med New study builds on encouraging data from initial small Phase II studies of savolit
Read more →HCMBlock Admission London: Wednesday, June 15 , 2016 : Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that an application has been made to the London Stock Exchange plc for a block admission
London: Wednesday, June 15, 2016: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that an application has been made to the London Stock Exchange plc for a block admission of 1,000,000 ordinary shares, par value of US$1.00 each ( Ordinary Shares ) to
Read more →HCMTotal Voting Rights London: Tuesday
London: Tuesday, May 31, 2016: For information purposes, Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) hereby notifies the market that as at May 31, 2016, the issued share capital of Chi-Med consisted of 60,649,342 ordinary shares of US$1.00 each, with each share
Read more →HCMChi-Med Completes Enrollment of 416 Patients in Pivotal Phase III FRESCO Trial with Fruquintinib in Colorectal Cancer London: Friday, May 13 , 2016 : Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today a
Chi-Med Completes Enrollment of 416 Patients in Pivotal Phase III FRESCO Trial with Fruquintinib in Colorectal Cancer London: Friday, May 13, 2016: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that it has completed patient enrollment of FRESCO,
Read more →HCMHutchison China MediTech Limited Announces Exercise of Overallotment Option London: Wednesday
Hutchison China MediTech Limited Announces Exercise of Overallotment Option London: Wednesday, April 13, 2016: Hutchison China MediTech Limited ( Chi-Med ) (Nasdaq/AIM: HCM) announces that the underwriters of its offering of American depositary shares ( ADSs ) on the Nasdaq Glo
Read more →HCMChi-Med initiates first-in-human clinical trial of novel PI3K inhibitor HMPL-689 London: Tuesday, April 12 , 2016 : Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma
Chi-Med initiates first-in-human clinical trial of novel PI3K inhibitor HMPL-689 London: Tuesday, April 12, 2016: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited ( HMP ), its drug R&D subsidiary, has initiated the
Read more →HCMDirector s Shareholding London: Tuesday , March 29 , 2016 : Hutchison China MediTech Limited ( Chi-Med ) (AIM / Nasdaq: HCM) received notification on
Director s Shareholding London: Tuesday, March 29, 2016: Hutchison China MediTech Limited ( Chi-Med ) (AIM / Nasdaq: HCM) received notification on March 25, 2016 that Mr Christian Hogg, Executive Director and Chief Executive Officer, has purchased 36,600 American Depositary Shar
Read more →HCM(Incorporated in the Cayman Islands with limited liability) (AIM Code: HCM) 15 March 2016 Dear Shareholder The Annual General Meeting (the AGM ) of Hutchison China MediTech Limited (the Company ) will be held at 4th Floo
(Incorporated in the Cayman Islands with limited liability) The Annual General Meeting (the AGM ) of Hutchison China MediTech Limited (the Company ) will be held at 4th Floor, Hutchison House, 5 Hester Road, Battersea, London SW11 4AN on Wednesday, 27 April 2016 at 10:00 am in a
Read more →HCMChi-Med initiates sulfatinib Phase III registration study in pancreatic neuroendocrine tumor patients London: Monday
Chi-Med initiates sulfatinib Phase III registration study in pancreatic neuroendocrine tumor patients London: Monday, March 21, 2016: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited ( HMP ), its drug R&D subsidiary
Read more →Competitive Position
How HCM ranks across every disease it competes inCompetitive Position is a premium feature
See how HCM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial